|
G |
Chrna4 |
cholinergic receptor nicotinic alpha 4 subunit |
multiple interactions |
ISO |
[Lobeline binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; [Lobeline binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; [Lobeline binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] inhibits the reaction [Nicotine results in increased phosphorylation of STAT3 protein]; Lobeline inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Lobeline results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein] |
CTD |
PMID:14645658 PMID:18448488 |
|
NCBI chr 3:168,136,246...168,157,839
|
|
G |
Chrna7 |
cholinergic receptor nicotinic alpha 7 subunit |
affects response to substance multiple interactions |
ISO |
CHRNA7 protein mutant form affects the susceptibility to Lobeline Lobeline binds to and results in decreased activity of CHRNA7 protein; Lobeline binds to and results in increased activity of CHRNA7 protein mutant form |
CTD |
PMID:10082212 |
|
NCBI chr 1:126,123,425...126,249,181
|
|
G |
Chrnb2 |
cholinergic receptor nicotinic beta 2 subunit |
multiple interactions |
ISO |
[Lobeline binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; [Lobeline binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; [Lobeline binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] inhibits the reaction [Nicotine results in increased phosphorylation of STAT3 protein]; Lobeline inhibits the reaction [epibatidine binds to [CHRNA4 protein binds to CHRNB2 protein]]; Lobeline results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein] |
CTD |
PMID:14645658 PMID:18448488 |
|
NCBI chr 2:175,181,402...175,189,619
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
ISO |
Lobeline results in decreased activity of KCNH2 protein |
CTD |
PMID:28551711 |
|
NCBI chr 4:11,719,357...11,751,424
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
[Lobeline binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; Lobeline inhibits the reaction [Nicotine results in decreased phosphorylation of MAPK1 protein] |
CTD |
PMID:18448488 PMID:20106947 |
|
NCBI chr11:97,462,025...97,529,193
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
[Lobeline binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; Lobeline inhibits the reaction [Nicotine results in decreased phosphorylation of MAPK3 protein] |
CTD |
PMID:18448488 PMID:20106947 |
|
NCBI chr 1:190,797,189...190,803,411
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO |
[Lobeline binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]] inhibits the reaction [Nicotine results in increased phosphorylation of STAT3 protein]; Lobeline inhibits the reaction [Nicotine results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:18448488 PMID:20106947 |
|
NCBI chr10:86,311,528...86,363,513
|
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
ISO |
[Clorgyline co-treated with Selegiline] inhibits the reaction [Norepinephrine results in increased expression of ACTA2 mRNA] |
CTD |
PMID:34609854 |
|
NCBI chr 1:241,159,723...241,172,503
|
|
G |
Aifm1 |
apoptosis inducing factor, mitochondria associated 1 |
multiple interactions |
ISO |
Selegiline inhibits the reaction [1-Methyl-4-phenylpyridinium affects the localization of AIFM1 protein]; Selegiline inhibits the reaction [Oxidopamine affects the localization of AIFM1 protein]; Selegiline inhibits the reaction [Rotenone affects the localization of AIFM1 protein] |
CTD |
PMID:12880480 |
|
NCBI chr X:132,528,107...132,567,237
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions increases phosphorylation |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Selegiline co-treated with 1-Methyl-4-phenylpyridinium] results in increased phosphorylation of AKT1 protein]; [Selegiline co-treated with 1-Methyl-4-phenylpyridinium] results in increased phosphorylation of AKT1 protein Selegiline results in increased phosphorylation of AKT1 protein |
CTD |
PMID:22019741 |
|
NCBI chr 6:137,534,810...137,555,131
|
|
G |
Bach1 |
BTB domain and CNC homolog 1 |
multiple interactions |
ISO |
Selegiline inhibits the reaction [Smoke analog affects the localization of BACH1 protein] |
CTD |
PMID:28108387 |
|
NCBI chr11:40,425,721...40,461,118
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
Selegiline inhibits the reaction [linsidomine results in increased expression of BAX protein] |
CTD |
PMID:12880480 |
|
NCBI chr 1:105,076,472...105,081,906
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
Selegiline inhibits the reaction [linsidomine results in decreased expression of BCL2 protein] |
CTD |
PMID:12880480 |
|
NCBI chr13:23,204,464...23,366,900
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
Selegiline inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of CASP3 mRNA]; Selegiline inhibits the reaction [linsidomine results in increased expression of CASP3 mRNA]; Selegiline inhibits the reaction [linsidomine results in increased expression of CASP3 protein] Selegiline promotes the reaction [Hydroxyurea results in increased cleavage of CASP3 protein] |
CTD |
PMID:12880480 PMID:14724376 PMID:23696560 |
|
NCBI chr16:52,395,539...52,413,794
|
|
G |
Cat |
catalase |
multiple interactions |
EXP ISO |
Selegiline promotes the reaction [Rotenone results in increased activity of CAT protein] Selegiline inhibits the reaction [Smoke analog results in decreased activity of CAT protein] |
CTD |
PMID:16490285 PMID:28108387 |
|
NCBI chr 3:110,297,340...110,329,526
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions |
ISO |
[Clorgyline co-treated with Selegiline] inhibits the reaction [Norepinephrine results in increased expression of COL1A1 mRNA] |
CTD |
PMID:34609854 |
|
NCBI chr10:80,380,458...80,397,461
|
|
G |
Col3a1 |
collagen type III alpha 1 chain |
multiple interactions |
ISO |
[Clorgyline co-treated with Selegiline] inhibits the reaction [Norepinephrine results in increased expression of COL3A1 mRNA] |
CTD |
PMID:34609854 |
|
NCBI chr 9:54,866,646...54,902,578
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions |
ISO |
Selegiline inhibits the reaction [linsidomine affects the localization of CYCS protein] |
CTD |
PMID:12880480 |
|
NCBI chr 4:80,982,667...80,984,767
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
affects metabolic processing |
ISO |
CYP1A2 protein affects the metabolism of Selegiline |
CTD |
PMID:16198659 |
|
NCBI chr 8:66,971,261...66,978,149
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
multiple interactions decreases activity |
ISO |
Selegiline inhibits the reaction [CYP2B6 protein results in increased hydroxylation of Bupropion] Selegiline results in decreased activity of CYP2B6 protein |
CTD |
PMID:25656918 |
|
NCBI chr 1:90,780,468...90,859,852
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
Selegiline inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of FOS mRNA] |
CTD |
PMID:14724376 |
|
NCBI chr 6:110,852,188...110,855,054
|
|
G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
multiple interactions |
ISO EXP |
Selegiline inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of GAPDH mRNA] Selegiline inhibits the reaction [Paraquat affects the localization of GAPDH protein] Selegiline inhibits the reaction [Hydroxyurea affects the localization of GAPDH protein] |
CTD |
PMID:14724376 PMID:20478973 PMID:23696560 |
|
NCBI chr 4:157,962,312...157,967,158
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO |
Selegiline inhibits the reaction [Smoke analog results in increased expression of HMOX1 protein] |
CTD |
PMID:28108387 |
|
NCBI chr19:13,452,365...13,479,823
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
ISO |
Selegiline inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of JUN mRNA] Selegiline results in increased expression of JUN protein |
CTD |
PMID:14724376 PMID:16099847 |
|
NCBI chr 5:115,009,900...115,012,993
|
|
G |
Maoa |
monoamine oxidase A |
decreases activity |
ISO |
Selegiline results in decreased activity of MAOA protein |
CTD |
PMID:31323226 |
|
NCBI chr X:8,615,239...8,681,372
|
|
G |
Maob |
monoamine oxidase B |
affects binding decreases activity multiple interactions |
ISO EXP |
Selegiline binds to MAOB protein Selegiline results in decreased activity of MAOB protein [Selegiline results in decreased activity of MAOB protein] which results in decreased abundance of 3,4-Dihydroxyphenylacetic Acid; [Selegiline results in decreased activity of MAOB protein] which results in decreased abundance of Homovanillic Acid; [Selegiline results in decreased activity of MAOB protein] which results in increased abundance of Dopamine [Selegiline results in decreased activity of MAOB protein] which results in increased susceptibility to Methamphetamine; zonisamide inhibits the reaction [Selegiline binds to MAOB protein] Selegiline inhibits the reaction [MAOB protein results in decreased amination of Dopamine]; Selegiline inhibits the reaction [MAOB protein results in increased degradation of Dopamine]; Selegiline inhibits the reaction [Smoke analog results in increased activity of MAOB protein] |
CTD |
PMID:1905457 PMID:15178694 PMID:15545290 PMID:16012872 PMID:16252076 PMID:19948168 PMID:21405131 PMID:21696156 PMID:21923181 PMID:21923198 PMID:26721607 PMID:28108387 PMID:28302559 PMID:30036687 PMID:31323226 More...
|
|
NCBI chr X:8,490,405...8,594,065
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Selegiline results in increased phosphorylation of MAPK1 protein] 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Selegiline co-treated with 1-Methyl-4-phenylpyridinium] results in increased phosphorylation of MAPK1 protein]; [Selegiline co-treated with 1-Methyl-4-phenylpyridinium] results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:16099847 PMID:22019741 |
|
NCBI chr11:97,462,025...97,529,193
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Selegiline results in increased phosphorylation of MAPK3 protein] 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Selegiline co-treated with 1-Methyl-4-phenylpyridinium] results in increased phosphorylation of MAPK3 protein]; [Selegiline co-treated with 1-Methyl-4-phenylpyridinium] results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:16099847 PMID:22019741 |
|
NCBI chr 1:190,797,189...190,803,411
|
|
G |
Mt1 |
metallothionein 1 |
multiple interactions |
ISO |
Selegiline inhibits the reaction [linsidomine results in increased expression of MT1 protein] |
CTD |
PMID:12880480 |
|
NCBI chr19:10,831,959...10,832,975
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
increases phosphorylation multiple interactions |
ISO |
Selegiline results in increased phosphorylation of MYC protein MYC protein affects the reaction [Selegiline results in increased expression of TXN] |
CTD |
PMID:16099847 |
|
NCBI chr 7:95,483,105...95,488,031
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions increases localization |
EXP ISO |
NFE2L2 mutant form inhibits the reaction [Selegiline inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased activity of NQO1 protein]]; NFE2L2 mutant form inhibits the reaction [Selegiline results in increased activity of NQO1 protein]; Selegiline inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased localization of NFE2L2 protein] Selegiline inhibits the reaction [Smoke analog affects the localization of NFE2L2 protein] Selegiline results in increased localization of NFE2L2 protein |
CTD |
PMID:22019741 PMID:28108387 |
|
NCBI chr 3:81,001,529...81,031,165
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions increases activity |
EXP ISO |
NFE2L2 mutant form inhibits the reaction [Selegiline inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased activity of NQO1 protein]]; NFE2L2 mutant form inhibits the reaction [Selegiline results in increased activity of NQO1 protein]; Selegiline inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased activity of NQO1 protein] Selegiline inhibits the reaction [Smoke analog results in increased expression of NQO1 protein] |
CTD |
PMID:22019741 PMID:28108387 |
|
NCBI chr19:52,205,374...52,220,267
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
Selegiline inhibits the reaction [linsidomine results in decreased expression of PARP1 protein] |
CTD |
PMID:12880480 |
|
NCBI chr13:94,839,484...94,871,295
|
|
G |
Prkn |
parkin RBR E3 ubiquitin protein ligase |
multiple interactions |
ISO |
Selegiline inhibits the reaction [linsidomine results in increased expression of PRKN protein] |
CTD |
PMID:12880480 |
|
NCBI chr 1:51,236,410...52,430,242
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
Selegiline inhibits the reaction [Smoke analog affects the localization of RELA protein] |
CTD |
PMID:28108387 |
|
NCBI chr 1:212,354,336...212,364,815
|
|
G |
Siah1 |
siah E3 ubiquitin protein ligase 1 |
multiple interactions |
EXP |
Selegiline inhibits the reaction [Paraquat affects the localization of SIAH1A protein] |
CTD |
PMID:20478973 |
|
NCBI chr19:36,552,165...36,575,773
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Selegiline inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:50,668,817...50,711,019
|
|
G |
Snca |
synuclein alpha |
multiple interactions |
ISO |
Selegiline inhibits the reaction [1,2,3,4-tetrahydro-1-(phenylmethyl)isoquinoline results in increased expression of SNCA protein]; Selegiline inhibits the reaction [linsidomine results in increased expression of SNCA protein] |
CTD |
PMID:12880480 PMID:15114628 |
|
NCBI chr 4:91,026,474...91,127,444
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO |
[Clorgyline co-treated with Selegiline] inhibits the reaction [Norepinephrine results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:34609854 |
|
NCBI chr10:86,311,528...86,363,513
|
|
G |
Th |
tyrosine hydroxylase |
multiple interactions decreases expression |
EXP |
Selegiline inhibits the reaction [Rotenone results in decreased expression of TH protein] Selegiline results in decreased expression of TH mRNA |
CTD |
PMID:11862330 PMID:16490285 |
|
NCBI chr 1:207,500,959...207,508,276
|
|
G |
Txn1 |
thioredoxin 1 |
multiple interactions increases expression affects response to substance |
ISO |
Dinitrochlorobenzene inhibits the reaction [Selegiline results in increased expression of TXN]; Dinitrochlorobenzene inhibits the reaction [TXN protein affects the susceptibility to Selegiline]; MYC protein affects the reaction [Selegiline results in increased expression of TXN] Selegiline results in increased expression of TXN protein |
CTD |
PMID:16099847 |
|
NCBI chr 5:77,507,455...77,519,685
|
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases methylation increases metabolic processing increases hydroxylation |
ISO |
CYP1A1 protein results in decreased methylation of almotriptan CYP1A1 protein results in increased metabolism of almotriptan CYP1A1 protein results in increased hydroxylation of almotriptan |
CTD |
PMID:12642466 |
|
NCBI chr 8:66,991,940...66,998,014
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases methylation |
ISO |
CYP1A2 protein results in decreased methylation of almotriptan |
CTD |
PMID:12642466 |
|
NCBI chr 8:66,971,261...66,978,149
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
decreases methylation |
ISO |
CYP2C19 protein results in decreased methylation of almotriptan |
CTD |
PMID:12642466 |
|
NCBI chr 1:247,879,058...247,916,804
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
decreases methylation |
ISO |
CYP2C8 protein results in decreased methylation of almotriptan |
CTD |
PMID:12642466 |
|
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
decreases methylation increases hydroxylation |
ISO |
CYP2D6 protein results in decreased methylation of almotriptan CYP2D6 protein results in increased hydroxylation of almotriptan |
CTD |
PMID:12642466 |
|
NCBI chr 7:115,762,662...115,771,832
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases hydroxylation decreases methylation |
ISO |
CYP3A4 protein results in increased hydroxylation of almotriptan CYP3A4 protein results in decreased methylation of almotriptan |
CTD |
PMID:12642466 |
|
NCBI chr12:14,321,771...14,343,886
|
|
G |
Fmo3 |
flavin containing dimethylaniline monoxygenase 3 |
increases oxidation |
ISO |
FMO3 protein results in increased oxidation of almotriptan |
CTD |
PMID:12642466 |
|
NCBI chr13:75,309,367...75,334,915
|
|
G |
Htr1b |
5-hydroxytryptamine receptor 1B |
multiple interactions |
ISO |
HTR1B affects the reaction [almotriptan inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]] |
CTD |
PMID:11134654 |
|
NCBI chr 8:91,395,405...91,414,815
|
|
G |
Maoa |
monoamine oxidase A |
increases metabolic processing |
ISO |
MAOA protein results in increased metabolism of almotriptan |
CTD |
PMID:12642466 |
|
NCBI chr X:8,615,239...8,681,372
|
|
|
G |
Htr1a |
5-hydroxytryptamine receptor 1A |
affects binding |
EXP |
alverine binds to HTR1A protein |
CTD |
PMID:11697552 |
|
NCBI chr 2:38,427,169...38,431,733
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
ISO |
alverine results in decreased activity of KCNH2 protein |
CTD |
PMID:28551711 |
|
NCBI chr 4:11,719,357...11,751,424
|
|
|
G |
Aadat |
aminoadipate aminotransferase |
affects expression |
EXP |
Amitriptyline affects the expression of AADAT mRNA |
CTD |
PMID:18355885 |
|
NCBI chr16:29,509,392...29,544,332
|
|
G |
Abat |
4-aminobutyrate aminotransferase |
decreases expression |
EXP |
Amitriptyline results in decreased expression of ABAT mRNA |
CTD |
PMID:21820738 |
|
NCBI chr10:7,503,351...7,599,474
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
decreases expression |
EXP |
Amitriptyline results in decreased expression of ABCB11 mRNA |
CTD |
PMID:27765674 |
|
NCBI chr 3:74,424,620...74,520,646
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
affects transport increases transport affects expression |
ISO EXP |
ABCB1A protein affects the transport of Amitriptyline ABCB1A protein results in increased transport of Amitriptyline; ABCB1A protein results in increased transport of Amitriptyline metabolite Amitriptyline affects the expression of ABCB1 mRNA |
CTD |
PMID:10700657 PMID:12082591 PMID:18355885 |
|
NCBI chr 4:26,312,403...26,488,456
|
|
G |
Abcd2 |
ATP binding cassette subfamily D member 2 |
decreases expression |
EXP |
Amitriptyline results in decreased expression of ABCD2 mRNA |
CTD |
PMID:22341215 |
|
NCBI chr 7:122,263,034...122,311,642
|
|
G |
Abcg5 |
ATP binding cassette subfamily G member 5 |
decreases expression |
EXP |
Amitriptyline results in decreased expression of ABCG5 mRNA |
CTD |
PMID:27765674 |
|
NCBI chr 6:9,965,118...9,990,563
|
|
G |
Abcg8 |
ATP binding cassette subfamily G member 8 |
decreases expression |
EXP |
Amitriptyline results in decreased expression of ABCG8 mRNA |
CTD |
PMID:27765674 |
|
NCBI chr 6:9,945,629...9,964,912
|
|
G |
Ace2 |
angiotensin converting enzyme 2 |
increases expression |
ISO |
Amitriptyline results in increased expression of ACE2 mRNA |
CTD |
PMID:32808185 |
|
NCBI chr X:30,293,597...30,340,961
|
|
G |
Ache |
acetylcholinesterase |
decreases expression increases activity |
EXP ISO |
Amitriptyline results in decreased expression of ACHE mRNA Amitriptyline results in increased activity of ACHE protein |
CTD |
PMID:21820738 PMID:29614332 |
|
NCBI chr12:25,042,882...25,050,608
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
affects expression |
EXP |
Amitriptyline affects the expression of ALDH1A1 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr 1:218,000,470...218,152,962
|
|
G |
Ankrd1 |
ankyrin repeat domain 1 |
increases expression |
EXP |
Amitriptyline results in increased expression of ANKRD1 mRNA |
CTD |
PMID:22341215 |
|
NCBI chr 1:233,815,851...233,834,891
|
|
G |
Ano3 |
anoctamin 3 |
decreases expression |
EXP |
Amitriptyline results in decreased expression of ANO3 mRNA |
CTD |
PMID:22341215 |
|
NCBI chr 3:97,235,671...97,550,090
|
|
G |
Ap1s1 |
adaptor related protein complex 1 subunit sigma 1 |
decreases expression |
ISO |
Amitriptyline results in decreased expression of AP1S1 mRNA |
CTD |
PMID:17175557 PMID:17567588 |
|
NCBI chr12:19,625,267...19,635,792
|
|
G |
Apoa4 |
apolipoprotein A4 |
affects expression |
EXP |
Amitriptyline affects the expression of APOA4 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr 8:55,435,779...55,438,160
|
|
G |
Arg1 |
arginase 1 |
increases expression |
EXP |
Amitriptyline results in increased expression of ARG1 mRNA |
CTD |
PMID:22341215 |
|
NCBI chr 1:22,295,093...22,307,720
|
|
G |
Asah1 |
N-acylsphingosine amidohydrolase 1 |
increases expression |
ISO |
Amitriptyline results in increased expression of ASAH1 mRNA |
CTD |
PMID:15342952 PMID:17175557 PMID:17567588 |
|
NCBI chr16:57,669,927...57,701,349
|
|
G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
increases expression |
ISO |
Amitriptyline results in increased expression of ASNS mRNA |
CTD |
PMID:15342952 PMID:17175557 PMID:17567588 |
|
NCBI chr 4:36,752,061...36,769,970
|
|
G |
Atf3 |
activating transcription factor 3 |
increases expression |
EXP |
Amitriptyline results in increased expression of ATF3 mRNA |
CTD |
PMID:22341215 |
|
NCBI chr13:105,274,103...105,331,653
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP |
Amitriptyline inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of BAX protein] |
CTD |
PMID:19135049 |
|
NCBI chr 1:105,076,472...105,081,906
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
EXP |
Amitriptyline inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of BCL2 protein] |
CTD |
PMID:19135049 |
|
NCBI chr13:23,204,464...23,366,900
|
|
G |
Bhmt |
betaine-homocysteine S-methyltransferase |
affects expression |
EXP |
Amitriptyline affects the expression of BHMT mRNA |
CTD |
PMID:18355885 |
|
NCBI chr 2:26,594,852...26,614,429
|
|
G |
C1qa |
complement C1q A chain |
increases expression |
EXP |
Amitriptyline results in increased expression of C1QA mRNA |
CTD |
PMID:22341215 |
|
NCBI chr 5:154,417,086...154,419,933
|
|
G |
C1qc |
complement C1q C chain |
increases expression |
EXP |
Amitriptyline results in increased expression of C1QC mRNA |
CTD |
PMID:22341215 |
|
NCBI chr 5:154,410,845...154,414,208
|
|
G |
Cacna2d1 |
calcium voltage-gated channel auxiliary subunit alpha2delta 1 |
increases expression |
EXP |
Amitriptyline results in increased expression of CACNA2D1 mRNA |
CTD |
PMID:22341215 |
|
NCBI chr 4:19,902,324...20,330,287
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
ISO |
Amitriptyline inhibits the reaction [7-ketocholesterol affects the localization of CASP1 protein]; Amitriptyline inhibits the reaction [7-ketocholesterol results in increased activity of CASP1 protein]; Amitriptyline inhibits the reaction [Cholesterol analog affects the localization of CASP1 protein]; Amitriptyline inhibits the reaction [Cholesterol analog results in increased activity of CASP1 protein] |
CTD |
PMID:28633109 |
|
NCBI chr 8:10,746,338...10,882,295
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases expression increases activity |
EXP |
Amitriptyline inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased activity of CASP3 protein] Amitriptyline results in increased expression of CASP3 mRNA Amitriptyline results in increased activity of CASP3 protein |
CTD |
PMID:16717317 PMID:19135049 PMID:19815060 |
|
NCBI chr16:52,395,539...52,413,794
|
|
G |
Casr |
calcium-sensing receptor |
decreases expression |
EXP |
Amitriptyline results in decreased expression of CASR mRNA |
CTD |
PMID:22341215 |
|
NCBI chr11:77,738,398...77,813,639
|
|
G |
Cat |
catalase |
decreases expression |
ISO |
Amitriptyline results in decreased expression of CAT protein |
CTD |
PMID:1937386 |
|
NCBI chr 3:110,297,340...110,329,526
|
|
G |
Cd74 |
CD74 molecule |
increases expression |
EXP |
Amitriptyline results in increased expression of CD74 mRNA |
CTD |
PMID:22341215 |
|
NCBI chr18:54,256,757...54,266,003
|
|
G |
Cdkn2c |
cyclin-dependent kinase inhibitor 2C |
affects expression |
EXP |
Amitriptyline affects the expression of CDKN2C mRNA |
CTD |
PMID:18355885 |
|
NCBI chr 5:129,639,736...129,645,564
|
|
G |
Ces2h |
carboxylesterase 2H |
affects expression |
EXP |
Amitriptyline affects the expression of CES2 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr19:32,974,242...32,988,842
|
|
G |
Chat |
choline O-acetyltransferase |
increases expression |
EXP |
Amitriptyline results in increased expression of CHAT mRNA |
CTD |
PMID:21820738 |
|
NCBI chr16:7,657,362...7,717,093
|
|
G |
Chrna3 |
cholinergic receptor nicotinic alpha 3 subunit |
decreases expression |
EXP |
Amitriptyline results in decreased expression of CHRNA3 mRNA |
CTD |
PMID:22341215 |
|
NCBI chr 8:55,401,668...55,415,165
|
|
G |
Chrnb2 |
cholinergic receptor nicotinic beta 2 subunit |
decreases expression increases response to substance |
EXP ISO |
Amitriptyline results in decreased expression of CHRNB2 mRNA CHRNB2 protein results in increased susceptibility to Amitriptyline |
CTD |
PMID:21820738 PMID:21905669 |
|
NCBI chr 2:175,181,402...175,189,619
|
|
G |
Cmtm6 |
CKLF-like MARVEL transmembrane domain containing 6 |
affects expression |
EXP |
Amitriptyline affects the expression of CMTM6 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr 8:114,422,934...114,441,034
|
|
G |
Cpne4 |
copine 4 |
decreases expression |
EXP |
Amitriptyline results in decreased expression of CPNE4 mRNA |
CTD |
PMID:22341215 |
|
NCBI chr 8:105,177,376...105,653,075
|
|
G |
Cpped1 |
calcineurin-like phosphoesterase domain containing 1 |
affects expression |
EXP |
Amitriptyline affects the expression of CPPED1 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr10:3,701,522...3,821,050
|
|
G |
Crem |
cAMP responsive element modulator |
affects expression |
EXP |
Amitriptyline affects the expression of CREM mRNA |
CTD |
PMID:18355885 |
|
NCBI chr17:58,932,011...59,001,160
|
|
G |
Csrp3 |
cysteine and glycine rich protein 3 |
increases expression |
EXP |
Amitriptyline results in increased expression of CSRP3 mRNA |
CTD |
PMID:22341215 |
|
NCBI chr 1:98,528,067...98,546,647
|
|
G |
Cybb |
cytochrome b-245 beta chain |
multiple interactions |
ISO |
Amitriptyline inhibits the reaction [7-ketocholesterol affects the localization of CYBB protein]; Amitriptyline inhibits the reaction [7-ketocholesterol analog affects the localization of CYBB protein] |
CTD |
PMID:28633109 |
|
NCBI chr X:16,030,596...16,065,065
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
increases metabolic processing multiple interactions |
ISO |
Amitriptyline results in increased metabolism of CYP1A2 protein; CYP1A2 protein results in increased metabolism of Amitriptyline [CYP1A2 protein co-treated with CYP2C9 protein co-treated with CYP3A4 protein co-treated with CYP2D6 protein co-treated with CYP2C19 protein] affects the susceptibility to Amitriptyline |
CTD |
PMID:18359012 PMID:23397584 PMID:27320963 |
|
NCBI chr 8:66,971,261...66,978,149
|
|
G |
Cyp2a1 |
cytochrome P450, family 2, subfamily a, polypeptide 1 |
affects expression |
EXP |
Amitriptyline affects the expression of CYP2A1 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr 1:82,231,611...82,244,887
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
increases expression |
EXP |
Amitriptyline results in increased expression of CYP2B1 mRNA |
CTD |
PMID:10945841 |
|
NCBI chr 1:90,646,098...90,669,762
|
|
G |
Cyp2b15 |
cytochrome P450, family 2, subfamily b, polypeptide 15 |
affects expression |
EXP |
Amitriptyline affects the expression of CYP2B15 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr 1:82,094,188...82,106,492
|
|
G |
Cyp2b2 |
cytochrome P450, family 2, subfamily b, polypeptide 2 |
increases expression |
EXP |
Amitriptyline results in increased expression of CYP2B2 mRNA |
CTD |
PMID:10945841 |
|
NCBI chr 1:90,722,243...90,736,272
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
increases metabolic processing |
ISO |
CYP2B6 protein results in increased metabolism of Amitriptyline |
CTD |
PMID:27320963 |
|
NCBI chr 1:90,780,468...90,859,852
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
multiple interactions increases metabolic processing |
ISO |
[CYP1A2 protein co-treated with CYP2C9 protein co-treated with CYP3A4 protein co-treated with CYP2D6 protein co-treated with CYP2C19 protein] affects the susceptibility to Amitriptyline CYP2C19 protein results in increased metabolism of Amitriptyline |
CTD |
PMID:23397584 PMID:27320963 |
|
NCBI chr 1:247,879,058...247,916,804
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
decreases activity multiple interactions increases metabolic processing |
ISO |
Amitriptyline results in decreased activity of CYP2D6 protein [CYP1A2 protein co-treated with CYP2C9 protein co-treated with CYP3A4 protein co-treated with CYP2D6 protein co-treated with CYP2C19 protein] affects the susceptibility to Amitriptyline Amitriptyline results in increased metabolism of CYP2D6 protein; CYP2D6 protein results in increased metabolism of Amitriptyline |
CTD |
PMID:16044105 PMID:18359012 PMID:18359183 PMID:23397584 PMID:27320963 |
|
NCBI chr 7:115,762,662...115,771,832
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases metabolic processing multiple interactions |
ISO |
Amitriptyline results in increased metabolism of CYP3A4 protein [CYP1A2 protein co-treated with CYP2C9 protein co-treated with CYP3A4 protein co-treated with CYP2D6 protein co-treated with CYP2C19 protein] affects the susceptibility to Amitriptyline |
CTD |
PMID:18359012 PMID:23397584 |
|
NCBI chr12:14,321,771...14,343,886
|
|
G |
Cyp3a23-3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 |
increases expression affects expression |
EXP |
Amitriptyline results in increased expression of CYP3A23-3A1 mRNA Amitriptyline affects the expression of CYP3A23-3A1 mRNA |
CTD |
PMID:10945841 PMID:18355885 |
|
NCBI chr12:14,369,950...14,398,803
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
increases metabolic processing |
ISO |
Amitriptyline results in increased metabolism of CYP3A5 protein |
CTD |
PMID:18359012 |
|
NCBI chr12:21,919,955...21,960,160
|
|
G |
Cyp4f4 |
cytochrome P450, family 4, subfamily f, polypeptide 4 |
affects expression |
EXP |
Amitriptyline affects the expression of CYP4F2 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr 7:11,717,208...11,733,507
|
|
G |
Dcaf8 |
DDB1 and CUL4 associated factor 8 |
affects expression |
EXP |
Amitriptyline affects the expression of DCAF8 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr13:87,141,940...87,199,859
|
|
G |
Depp1 |
DEPP autophagy regulator 1 |
increases expression |
ISO |
Amitriptyline results in increased expression of DEPP1 mRNA |
CTD |
PMID:15342952 PMID:17175557 PMID:17567588 |
|
NCBI chr 4:149,910,794...149,913,013
|
|
G |
Des |
desmin |
multiple interactions |
ISO |
Amitriptyline inhibits the reaction [Homocysteine results in increased expression of DES protein] |
CTD |
PMID:23024785 |
|
NCBI chr 9:84,299,626...84,307,344
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
decreases activity |
EXP |
Amitriptyline results in decreased activity of DNMT1 protein Amitriptyline decreases activity of Dnmt1 protein in astrocyte nucleus |
CTD RGD |
PMID:19924110 PMID:22880885 |
RGD:9588218 |
NCBI chr 8:19,440,611...19,486,659
|
|
G |
Drd1 |
dopamine receptor D1 |
increases expression |
EXP |
Amitriptyline results in increased expression of DRD1 mRNA |
CTD |
PMID:16499906 |
|
NCBI chr17:10,545,488...10,550,029
|
|
G |
Drd3 |
dopamine receptor D3 |
increases expression |
EXP |
Amitriptyline results in increased expression of DRD3 mRNA |
CTD |
PMID:21820738 |
|
NCBI chr11:70,385,586...70,437,793
|
|
G |
Ecel1 |
endothelin converting enzyme-like 1 |
increases expression |
EXP |
Amitriptyline results in increased expression of ECEL1 mRNA |
CTD |
PMID:22341215 |
|
NCBI chr 9:95,267,417...95,276,508
|
|
G |
Eif4b |
eukaryotic translation initiation factor 4B |
affects expression |
EXP |
Amitriptyline affects the expression of EIF4B mRNA |
CTD |
PMID:18355885 |
|
NCBI chr 7:135,085,259...135,107,054
|
|
G |
Ephx1 |
epoxide hydrolase 1 |
affects expression |
EXP |
Amitriptyline affects the expression of EPHX1 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr13:95,246,079...95,275,852
|
|
G |
Erp29 |
endoplasmic reticulum protein 29 |
affects expression |
EXP |
Amitriptyline affects the expression of ERP29 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr12:40,750,177...40,756,607
|
|
G |
Fabp1 |
fatty acid binding protein 1 |
increases expression |
ISO |
Amitriptyline results in increased expression of FABP1 mRNA |
CTD |
PMID:15342952 PMID:17175557 PMID:17567588 |
|
NCBI chr 4:104,744,302...104,753,119
|
|
G |
Flrt3 |
fibronectin leucine rich transmembrane protein 3 |
increases expression |
EXP |
Amitriptyline results in increased expression of FLRT3 mRNA |
CTD |
PMID:22341215 |
|
NCBI chr 3:127,994,491...128,008,137
|
|
G |
Fmo3 |
flavin containing dimethylaniline monoxygenase 3 |
increases metabolic processing |
ISO |
FMO3 protein results in increased metabolism of Amitriptyline |
CTD |
PMID:27320963 |
|
NCBI chr13:75,309,367...75,334,915
|
|
G |
Fndc4 |
fibronectin type III domain containing 4 |
increases expression |
ISO |
Amitriptyline results in increased expression of FNDC4 mRNA |
CTD |
PMID:15342952 PMID:17175557 |
|
NCBI chr 6:25,077,155...25,080,812
|
|
G |
Gabra1 |
gamma-aminobutyric acid type A receptor subunit alpha 1 |
increases expression decreases expression |
EXP |
Amitriptyline results in increased expression of GABRA1 mRNA Amitriptyline results in decreased expression of GABRA1 mRNA |
CTD |
PMID:21820738 PMID:22341215 |
|
NCBI chr10:27,096,731...27,152,563
|
|
G |
Gabra2 |
gamma-aminobutyric acid type A receptor subunit alpha 2 |
increases expression |
EXP |
Amitriptyline results in increased expression of GABRA2 mRNA |
CTD |
PMID:21820738 |
|
NCBI chr14:37,451,218...37,587,458
|
|
G |
Gabra4 |
gamma-aminobutyric acid type A receptor subunit alpha 4 |
increases expression |
EXP |
Amitriptyline results in increased expression of GABRA4 mRNA |
CTD |
PMID:21820738 |
|
NCBI chr14:36,590,782...36,667,724
|
|
G |
Gabrb3 |
gamma-aminobutyric acid type A receptor subunit beta 3 |
increases expression |
EXP |
Amitriptyline results in increased expression of GABRB3 mRNA |
CTD |
PMID:21820738 |
|
NCBI chr 1:117,602,772...117,838,230
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
increases expression |
EXP |
Amitriptyline results in increased expression of GADD45A mRNA |
CTD |
PMID:22341215 |
|
NCBI chr 4:97,484,497...97,486,799
|
|
G |
Gal |
galanin and GMAP prepropeptide |
increases expression |
EXP |
Amitriptyline results in increased expression of GAL mRNA |
CTD |
PMID:22341215 |
|
NCBI chr 1:210,079,709...210,084,572
|
|
G |
Gckr |
glucokinase regulator |
affects expression |
EXP |
Amitriptyline affects the expression of GCKR mRNA |
CTD |
PMID:18355885 |
|
NCBI chr 6:25,044,592...25,075,834
|
|
G |
Gdpd3 |
glycerophosphodiester phosphodiesterase domain containing 3 |
increases expression |
ISO |
Amitriptyline results in increased expression of GDPD3 mRNA |
CTD |
PMID:15342952 PMID:17175557 PMID:17567588 |
|
NCBI chr 1:181,373,505...181,383,063
|
|
G |
Gfap |
glial fibrillary acidic protein |
increases expression |
EXP |
Amitriptyline results in increased expression of GFAP mRNA |
CTD |
PMID:22954530 |
|
NCBI chr10:88,352,987...88,361,661
|
|
G |
Gls2 |
glutaminase 2 |
affects expression |
EXP |
Amitriptyline affects the expression of GLS2 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr 7:617,252...633,424
|
|
G |
Got2 |
glutamic-oxaloacetic transaminase 2 |
affects expression |
EXP |
Amitriptyline affects the expression of GOT2 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr19:9,180,428...9,206,113
|
|
G |
Grb14 |
growth factor receptor bound protein 14 |
affects expression |
EXP |
Amitriptyline affects the expression of GRB14 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr 3:49,568,210...49,683,805
|
|
G |
Grik1 |
glutamate ionotropic receptor kainate type subunit 1 |
decreases expression |
EXP |
Amitriptyline results in decreased expression of GRIK1 mRNA |
CTD |
PMID:22341215 |
|
NCBI chr11:27,169,739...27,571,131
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
decreases activity |
ISO |
Amitriptyline results in decreased activity of GSTP1 protein |
CTD |
PMID:15094841 |
|
NCBI chr 1:210,767,237...210,770,242
|
|
G |
Hal |
histidine ammonia lyase |
affects expression |
EXP |
Amitriptyline affects the expression of HAL mRNA |
CTD |
PMID:18355885 |
|
NCBI chr 7:28,007,449...28,037,701
|
|
G |
Hmgb2 |
high mobility group box 2 |
affects expression |
EXP |
Amitriptyline affects the expression of HMGB2 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr16:37,721,374...37,723,950
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
increases expression |
ISO |
Amitriptyline results in increased expression of HMGCS1 mRNA |
CTD |
PMID:16324787 |
|
NCBI chr 2:53,379,457...53,399,807
|
|
G |
Hoxd1 |
homeo box D1 |
decreases expression |
EXP |
Amitriptyline results in decreased expression of HOXD1 mRNA |
CTD |
PMID:22341215 |
|
NCBI chr 3:59,665,629...59,667,769
|
|
G |
Hpn |
hepsin |
increases expression |
ISO |
Amitriptyline results in increased expression of HPN mRNA |
CTD |
PMID:15342952 PMID:17175557 PMID:17567588 |
|
NCBI chr 1:86,337,085...86,352,785
|
|
G |
Hpse |
heparanase |
decreases expression |
EXP |
Amitriptyline results in decreased expression of HPSE mRNA |
CTD |
PMID:22341215 |
|
NCBI chr14:9,200,971...9,241,377
|
|
G |
Hs3st2 |
heparan sulfate-glucosamine 3-sulfotransferase 2 |
decreases expression |
EXP |
Amitriptyline results in decreased expression of HS3ST2 mRNA |
CTD |
PMID:22341215 |
|
NCBI chr 1:175,956,161...176,077,400
|
|
G |
Htr1a |
5-hydroxytryptamine receptor 1A |
increases expression |
EXP |
Amitriptyline results in increased expression of HTR1A protein |
CTD |
PMID:1589591 |
|
NCBI chr 2:38,427,169...38,431,733
|
|
G |
Htr1d |
5-hydroxytryptamine receptor 1D |
decreases expression |
EXP |
Amitriptyline results in decreased expression of HTR1D mRNA |
CTD |
PMID:22341215 |
|
NCBI chr 5:153,939,735...153,960,012
|
|
G |
Htr2c |
5-hydroxytryptamine receptor 2C |
affects binding |
ISO |
Amitriptyline binds to HTR2C protein |
CTD |
PMID:18083778 |
|
NCBI chr X:115,453,190...115,682,325
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
Amitriptyline inhibits the reaction [7-ketocholesterol results in increased expression of IL1B protein]; Amitriptyline inhibits the reaction [Cholesterol analog results in increased expression of IL1B protein] |
CTD |
PMID:28633109 |
|
NCBI chr 3:137,030,200...137,036,581
|
|
G |
Il33 |
interleukin 33 |
affects expression |
EXP |
Amitriptyline affects the expression of IL33 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr 1:227,701,964...227,736,374
|
|
G |
Inhbe |
inhibin subunit beta E |
increases expression |
ISO |
Amitriptyline results in increased expression of INHBE mRNA |
CTD |
PMID:15342952 PMID:17175557 PMID:17567588 |
|
NCBI chr 7:65,061,531...65,064,519
|
|
G |
Itgb6 |
integrin subunit beta 6 |
decreases expression |
EXP |
Amitriptyline results in decreased expression of ITGB6 mRNA |
CTD |
PMID:22341215 |
|
NCBI chr 3:45,046,295...45,170,532
|
|
G |
Kcna4 |
potassium voltage-gated channel subfamily A member 4 |
decreases expression |
EXP |
Amitriptyline results in decreased expression of KCNA4 mRNA |
CTD |
PMID:22341215 |
|
NCBI chr 3:93,756,399...93,778,004
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
multiple interactions |
ISO |
Amitriptyline inhibits the reaction [KCNH2 protein results in increased transport of Thallium] |
CTD |
PMID:19583963 PMID:21158687 |
|
NCBI chr 4:11,719,357...11,751,424
|
|
G |
Kcnn2 |
potassium calcium-activated channel subfamily N member 2 |
decreases activity |
EXP |
Amitriptyline results in decreased activity of KCNN2 protein |
CTD |
PMID:10915830 |
|
NCBI chr18:40,004,693...40,445,043
|
|
G |
Kcns1 |
potassium voltage-gated channel, modifier subfamily S, member 1 |
decreases expression |
EXP |
Amitriptyline results in decreased expression of KCNS1 mRNA |
CTD |
PMID:22341215 |
|
NCBI chr 3:152,835,642...152,843,032
|
|
G |
Kcns3 |
potassium voltage-gated channel, modifier subfamily S, member 3 |
decreases expression |
EXP |
Amitriptyline results in decreased expression of KCNS3 mRNA |
CTD |
PMID:22341215 |
|
NCBI chr 6:33,808,314...33,865,018
|
|
G |
Lox |
lysyl oxidase |
affects expression |
EXP |
Amitriptyline affects the expression of LOX mRNA |
CTD |
PMID:18355885 |
|
NCBI chr18:45,964,544...45,977,431
|
|
G |
Lss |
lanosterol synthase |
increases expression |
ISO |
Amitriptyline results in increased expression of LSS mRNA |
CTD |
PMID:15342952 PMID:17175557 PMID:17567588 |
|
NCBI chr20:12,090,641...12,118,230
|
|
G |
Macroh2a1 |
macroH2A.1 histone |
affects expression |
EXP |
Amitriptyline affects the expression of MACROH2A1 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr17:8,479,331...8,542,071
|
|
G |
Manba |
mannosidase beta |
affects expression |
EXP |
Amitriptyline affects the expression of MANBA mRNA |
CTD |
PMID:18355885 |
|
NCBI chr 2:223,910,432...224,002,988
|
|
G |
Maoa |
monoamine oxidase A |
affects expression |
EXP |
Amitriptyline affects the expression of MAOA mRNA |
CTD |
PMID:21820738 |
|
NCBI chr X:8,615,239...8,681,372
|
|
G |
Mlx |
MAX dimerization protein MLX |
affects expression |
EXP |
Amitriptyline affects the expression of MLX mRNA |
CTD |
PMID:18355885 |
|
NCBI chr10:86,519,517...86,524,607
|
|
G |
Mmp16 |
matrix metallopeptidase 16 |
increases expression |
EXP |
Amitriptyline results in increased expression of MMP16 mRNA |
CTD |
PMID:22341215 |
|
NCBI chr 5:31,312,280...31,556,276
|
|
G |
Mrps18b |
mitochondrial ribosomal protein S18B |
affects expression |
EXP |
Amitriptyline affects the expression of MRPS18B mRNA |
CTD |
PMID:18355885 |
|
NCBI chr20:2,842,978...2,849,065
|
|
G |
Msmo1 |
methylsterol monooxygenase 1 |
affects expression |
EXP |
Amitriptyline affects the expression of MSMO1 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr16:24,980,680...24,997,927
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
ISO |
Amitriptyline inhibits the reaction [7-ketocholesterol affects the localization of NLRP3 protein]; Amitriptyline inhibits the reaction [Cholesterol analog affects the localization of NLRP3 protein] |
CTD |
PMID:28633109 |
|
NCBI chr10:44,826,299...44,853,373
|
|
G |
Nmb |
neuromedin B |
decreases expression |
EXP |
Amitriptyline results in decreased expression of NMB mRNA |
CTD |
PMID:22341215 |
|
NCBI chr 1:134,869,446...134,875,507
|
|
G |
Nmur1 |
neuromedin U receptor 1 |
decreases expression |
EXP |
Amitriptyline results in decreased expression of NMUR1 mRNA |
CTD |
PMID:21820738 |
|
NCBI chr 9:94,480,002...94,486,147
|
|
G |
Nog |
noggin |
decreases expression |
EXP |
Amitriptyline results in decreased expression of NOG mRNA |
CTD |
PMID:22341215 |
|
NCBI chr10:74,625,874...74,627,501
|
|
G |
Nphs2 |
NPHS2 stomatin family member, podocin |
multiple interactions |
ISO |
Amitriptyline inhibits the reaction [Homocysteine results in decreased expression of NPHS2 protein] |
CTD |
PMID:23024785 |
|
NCBI chr13:68,448,720...68,461,312
|
|
G |
Npy |
neuropeptide Y |
increases expression |
EXP |
Amitriptyline results in increased expression of NPY mRNA |
CTD |
PMID:22341215 |
|
NCBI chr 4:80,212,111...80,219,310
|
|
G |
Npy5r |
neuropeptide Y receptor Y5 |
increases expression |
EXP |
Amitriptyline results in increased expression of NPY5R mRNA |
CTD |
PMID:21820738 |
|
NCBI chr16:23,055,427...23,063,384
|
|
G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
increases expression |
ISO |
Amitriptyline results in increased expression of NR0B2 mRNA |
CTD |
PMID:15342952 PMID:17175557 |
|
NCBI chr 5:145,779,294...145,782,609
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
affects response to substance |
ISO |
NR3C1 protein affects the susceptibility to Amitriptyline |
CTD |
PMID:11226678 |
|
NCBI chr18:31,522,783...31,644,508
|
|
G |
Nr3c2 |
nuclear receptor subfamily 3, group C, member 2 |
increases expression |
EXP |
Amitriptyline results in increased expression of NR3C2 mRNA |
CTD |
PMID:12393271 |
|
NCBI chr19:47,619,853...47,964,089
|
|
G |
Nrep |
neuronal regeneration related protein |
affects expression |
EXP |
Amitriptyline affects the expression of NREP mRNA |
CTD |
PMID:18355885 |
|
NCBI chr18:25,291,219...25,320,742
|
|
G |
Ntng1 |
netrin G1 |
decreases expression |
EXP |
Amitriptyline results in decreased expression of NTNG1 mRNA |
CTD |
PMID:22341215 |
|
NCBI chr 2:197,462,785...197,827,681
|
|
G |
Nupr1 |
nuclear protein 1, transcriptional regulator |
increases expression |
ISO |
Amitriptyline results in increased expression of NUPR1 mRNA |
CTD |
PMID:15342952 PMID:17175557 PMID:17567588 |
|
NCBI chr 1:190,643,866...190,645,901
|
|
G |
Oaf |
out at first homolog |
affects expression |
EXP |
Amitriptyline affects the expression of OAF mRNA |
CTD |
PMID:18355885 |
|
NCBI chr 8:43,594,362...43,612,334
|
|
G |
Patj |
PATJ, crumbs cell polarity complex component |
decreases expression |
EXP |
Amitriptyline results in decreased expression of PATJ mRNA |
CTD |
PMID:22341215 |
|
NCBI chr 5:113,061,985...113,364,807
|
|
G |
Pc |
pyruvate carboxylase |
affects expression |
EXP |
Amitriptyline affects the expression of PC mRNA |
CTD |
PMID:18355885 |
|
NCBI chr 1:211,228,708...211,327,792
|
|
G |
Pecr |
peroxisomal trans-2-enoyl-CoA reductase |
affects expression |
EXP |
Amitriptyline affects the expression of PECR mRNA |
CTD |
PMID:18355885 |
|
NCBI chr 9:73,897,877...73,926,511
|
|
G |
Phyh |
phytanoyl-CoA 2-hydroxylase |
increases expression |
ISO |
Amitriptyline results in increased expression of PHYH mRNA |
CTD |
PMID:15342952 |
|
NCBI chr17:73,329,461...73,346,359
|
|
G |
Plcd4 |
phospholipase C, delta 4 |
decreases expression |
EXP |
Amitriptyline results in decreased expression of PLCD4 mRNA |
CTD |
PMID:22341215 |
|
NCBI chr 9:76,115,523...76,158,602
|
|
G |
Plpp4 |
phospholipid phosphatase 4 |
decreases expression |
EXP |
Amitriptyline results in decreased expression of PLPP4 mRNA |
CTD |
PMID:22341215 |
|
NCBI chr 1:183,829,794...183,959,319
|
|
G |
Por |
cytochrome p450 oxidoreductase |
affects expression |
EXP |
Amitriptyline affects the expression of POR mRNA |
CTD |
PMID:18355885 |
|
NCBI chr12:26,587,674...26,655,612
|
|
G |
Prokr1 |
prokineticin receptor 1 |
decreases expression |
EXP |
Amitriptyline results in decreased expression of PROKR1 mRNA |
CTD |
PMID:21820738 |
|
NCBI chr 4:120,022,301...120,033,367
|
|
G |
Pycard |
PYD and CARD domain containing |
multiple interactions |
ISO |
Amitriptyline inhibits the reaction [7-ketocholesterol affects the localization of PYCARD protein]; Amitriptyline inhibits the reaction [Cholesterol analog affects the localization of PYCARD protein] |
CTD |
PMID:28633109 |
|
NCBI chr 1:192,032,124...192,033,419
|
|
G |
Rasd1 |
ras related dexamethasone induced 1 |
increases expression |
EXP |
Amitriptyline results in increased expression of RASD1 mRNA |
CTD |
PMID:22341215 |
|
NCBI chr10:45,265,975...45,275,279
|
|
G |
Rbl2 |
RB transcriptional corepressor like 2 |
affects expression |
EXP |
Amitriptyline affects the expression of RBL2 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr19:32,049,690...32,096,467
|
|
G |
Reg3b |
regenerating family member 3 beta |
increases expression |
EXP |
Amitriptyline results in increased expression of REG3B mRNA |
CTD |
PMID:22341215 |
|
NCBI chr 4:110,861,775...110,865,015
|
|
G |
Rnf112 |
ring finger protein 112 |
decreases expression |
EXP |
Amitriptyline results in decreased expression of RNF112 mRNA |
CTD |
PMID:22341215 |
|
NCBI chr10:46,620,602...46,655,745
|
|
G |
RT1-Da |
RT1 class II, locus Da |
increases expression |
EXP |
Amitriptyline results in increased expression of RT1-DA mRNA |
CTD |
PMID:22341215 |
|
NCBI chr20:4,513,464...4,518,457
|
|
G |
RT1-Db1 |
RT1 class II, locus Db1 |
increases expression |
EXP |
Amitriptyline results in increased expression of RT1-DB1 mRNA |
CTD |
PMID:22341215 |
|
NCBI chr20:4,548,664...4,558,237
|
|
G |
RT1-S3 |
RT1 class Ib, locus S3 |
affects expression |
EXP |
Amitriptyline affects the expression of RT1-S3 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr20:2,670,654...2,675,411
|
|
G |
Scd |
stearoyl-CoA desaturase |
increases expression |
ISO |
Amitriptyline results in increased expression of SCD mRNA |
CTD |
PMID:16324787 |
|
NCBI chr 1:253,218,968...253,232,101
|
|
G |
Scn11a |
sodium voltage-gated channel alpha subunit 11 |
decreases expression |
EXP |
Amitriptyline results in decreased expression of SCN11A mRNA |
CTD |
PMID:22341215 |
|
NCBI chr 8:119,495,550...119,567,044
|
|
G |
Sema6a |
semaphorin 6A |
increases expression |
EXP |
Amitriptyline results in increased expression of SEMA6A mRNA |
CTD |
PMID:22341215 |
|
NCBI chr18:40,050,623...40,171,954
|
|
G |
Serpina3n |
serpin family A member 3N |
increases expression |
ISO |
Amitriptyline results in increased expression of SERPINA3 mRNA |
CTD |
PMID:15342952 PMID:17175557 PMID:17567588 |
|
NCBI chr 6:123,323,623...123,331,181
|
|
G |
Sh3gl3 |
SH3 domain containing GRB2 like 3, endophilin A3 |
affects expression |
EXP |
Amitriptyline affects the expression of SH3GL3 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr 1:136,124,500...136,255,669
|
|
G |
Slc22a1 |
solute carrier family 22 member 1 |
multiple interactions decreases activity |
ISO |
Amitriptyline inhibits the reaction [SLC22A1 protein results in increased import of 4-(4-(dimethylamino)styryl)-1-methylpyridinium iodide] Amitriptyline results in decreased activity of SLC22A1 protein |
CTD |
PMID:30189235 PMID:31364238 |
|
NCBI chr 1:50,624,339...50,651,437
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions decreases activity |
ISO |
Amitriptyline inhibits the reaction [SLC22A2 protein results in increased import of 4-(4-(dimethylamino)styryl)-1-methylpyridinium iodide]; Amitriptyline inhibits the reaction [SLC22A2 protein results in increased import of Tetraethylammonium]; Amitriptyline inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]; Amitriptyline inhibits the reaction [SLC22A2 protein results in increased uptake of Tetraethylammonium] Amitriptyline results in decreased activity of SLC22A2 protein |
CTD |
PMID:21599003 PMID:23770354 PMID:28629854 PMID:30189235 PMID:31364238 |
|
NCBI chr 1:50,668,817...50,711,019
|
|
G |
Slc22a6 |
solute carrier family 22 member 6 |
multiple interactions |
ISO |
Amitriptyline inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid] |
CTD |
PMID:21561794 |
|
NCBI chr 1:205,522,579...205,531,179
|
|
G |
Slc2a3 |
solute carrier family 2 member 3 |
decreases expression |
ISO |
Amitriptyline results in decreased expression of SLC2A3 mRNA |
CTD |
PMID:15342952 PMID:17175557 PMID:17567588 |
|
NCBI chr 4:157,632,887...157,698,034
|
|
G |
Slc47a2 |
solute carrier family 47 member 2 |
multiple interactions |
ISO |
Amitriptyline inhibits the reaction [SLC47A2 protein results in increased import of Tetraethylammonium] |
CTD |
PMID:28629854 |
|
NCBI chr10:46,490,262...46,532,954
|
|
G |
Slc6a6 |
solute carrier family 6 member 6 |
affects expression |
EXP |
Amitriptyline affects the expression of SLC6A6 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr 4:124,195,186...124,268,880
|
|
G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
affects expression |
EXP |
Amitriptyline affects the expression of SLCO1A4 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr 4:174,710,004...174,764,810
|
|
G |
Smagp |
small cell adhesion glycoprotein |
increases expression |
EXP |
Amitriptyline results in increased expression of SMAGP mRNA |
CTD |
PMID:22341215 |
|
NCBI chr 7:131,720,260...131,738,711
|
|
G |
Smpd1 |
sphingomyelin phosphodiesterase 1 |
multiple interactions increases response to substance decreases activity |
ISO |
[Amitriptyline results in decreased expression of and results in decreased activity of SMPD1 protein] which results in decreased abundance of Ceramides; Amitriptyline results in decreased expression of and results in decreased activity of SMPD1 protein SMPD1 protein results in increased susceptibility to Amitriptyline Amitriptyline results in decreased activity of SMPD1 protein |
CTD |
PMID:23770692 |
|
NCBI chr 1:169,304,772...169,308,615
|
|
G |
Sod1 |
superoxide dismutase 1 |
increases expression |
EXP |
Amitriptyline results in increased expression of SOD1 mRNA |
CTD |
PMID:10721683 |
|
NCBI chr11:42,942,742...42,948,399
|
|
G |
Sorl1 |
sortilin related receptor 1 |
decreases expression |
EXP |
Amitriptyline results in decreased expression of SORL1 mRNA |
CTD |
PMID:22341215 |
|
NCBI chr 8:51,238,713...51,401,458
|
|
G |
Sox11 |
SRY-box transcription factor 11 |
increases expression |
EXP |
Amitriptyline results in increased expression of SOX11 mRNA |
CTD |
PMID:22341215 |
|
NCBI chr 6:44,008,333...44,010,354
|
|
G |
Sprr1a |
small proline-rich protein 1A |
increases expression |
EXP |
Amitriptyline results in increased expression of SPRR1A mRNA |
CTD |
PMID:22341215 |
|
NCBI chr 2:180,750,709...180,752,625
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions |
ISO |
Amitriptyline results in increased cleavage of and results in increased activity of SREBF1 protein |
CTD |
PMID:16324787 |
|
NCBI chr10:45,507,152...45,529,164
|
|
G |
Srebf2 |
sterol regulatory element binding transcription factor 2 |
multiple interactions |
ISO |
Amitriptyline results in increased cleavage of and results in increased activity of SREBF2 protein |
CTD |
PMID:16324787 |
|
NCBI chr 7:115,542,774...115,600,945
|
|
G |
Sstr1 |
somatostatin receptor 1 |
decreases expression |
EXP |
Amitriptyline results in decreased expression of SSTR1 mRNA |
CTD |
PMID:21820738 |
|
NCBI chr 6:75,832,292...75,836,806
|
|
G |
St13 |
ST13, Hsp70 interacting protein |
affects expression |
EXP |
Amitriptyline affects the expression of ST13 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr 7:114,769,758...114,805,877
|
|
G |
Stac2 |
SH3 and cysteine rich domain 2 |
increases expression |
EXP |
Amitriptyline results in increased expression of STAC2 mRNA |
CTD |
PMID:22341215 |
|
NCBI chr10:83,032,418...83,048,260
|
|
G |
Stbd1 |
starch binding domain 1 |
affects expression |
EXP |
Amitriptyline affects the expression of STBD1 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr14:15,470,452...15,473,857
|
|
G |
Stmn1 |
stathmin 1 |
affects expression |
EXP |
Amitriptyline affects the expression of STMN1 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr 5:151,964,308...151,970,843
|
|
G |
Stmn4 |
stathmin 4 |
increases expression |
EXP |
Amitriptyline results in increased expression of STMN4 mRNA |
CTD |
PMID:22341215 |
|
NCBI chr15:40,541,305...40,559,253
|
|
G |
Tagln |
transgelin |
decreases expression |
ISO |
Amitriptyline results in decreased expression of TAGLN mRNA |
CTD |
PMID:15342952 PMID:17175557 PMID:17567588 |
|
NCBI chr 8:55,121,647...55,127,121
|
|
G |
Tex261 |
testis expressed 261 |
affects expression |
EXP |
Amitriptyline affects the expression of TEX261 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr 4:116,253,547...116,260,730
|
|
G |
Tgm1 |
transglutaminase 1 |
increases expression |
EXP |
Amitriptyline results in increased expression of TGM1 mRNA |
CTD |
PMID:22341215 |
|
NCBI chr15:29,191,039...29,206,000
|
|
G |
Timm10b |
translocase of inner mitochondrial membrane 10B |
affects expression |
EXP |
Amitriptyline affects the expression of TIMM10B mRNA |
CTD |
PMID:18355885 |
|
NCBI chr 1:169,392,355...169,395,201
|
|
G |
Trh |
thyrotropin releasing hormone |
multiple interactions |
ISO |
Amitriptyline inhibits the reaction [TRH protein results in decreased expression of TSHB protein] |
CTD |
PMID:6455462 |
|
NCBI chr 4:124,742,111...124,777,094
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
multiple interactions |
EXP |
Amitriptyline inhibits the reaction [[Capsaicin results in increased activity of TRPV1 protein] which results in increased uptake of Calcium] |
CTD |
PMID:23264033 |
|
NCBI chr10:58,349,936...58,375,021
|
|
G |
Tshb |
thyroid stimulating hormone subunit beta |
multiple interactions |
ISO |
Amitriptyline inhibits the reaction [TRH protein results in decreased expression of TSHB protein] |
CTD |
PMID:6455462 |
|
NCBI chr 2:190,224,676...190,229,559
|
|
G |
Uba52 |
ubiquitin A-52 residue ribosomal protein fusion product 1 |
affects expression |
EXP |
Amitriptyline affects the expression of UBA52 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr16:18,952,583...18,954,780
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
affects expression |
EXP |
Amitriptyline affects the expression of UGT1A1 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr 9:96,249,143...96,256,264
|
|
G |
Ugt2a1 |
UDP glucuronosyltransferase family 2 member A1 |
affects expression |
EXP |
Amitriptyline affects the expression of UGT2A1 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr14:20,521,018...20,545,934
|
|
G |
Ugt2b1 |
UDP glucuronosyltransferase 2 family, polypeptide B1 |
affects expression |
EXP |
Amitriptyline affects the expression of UGT2B1 mRNA |
CTD |
PMID:18355885 |
|
NCBI chr14:21,378,882...21,390,631
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
Amitriptyline inhibits the reaction [Homocysteine results in decreased secretion of VEGFA protein] |
CTD |
PMID:23024785 |
|
NCBI chr 9:22,452,854...22,468,194
|
|
G |
Wipi1 |
WD repeat domain, phosphoinositide interacting 1 |
increases expression |
ISO |
Amitriptyline results in increased expression of WIPI1 mRNA |
CTD |
PMID:15342952 PMID:17175557 |
|
NCBI chr10:95,042,451...95,079,679
|
|
|
G |
Hrh1 |
histamine receptor H 1 |
multiple interactions |
ISO |
azatadine binds to and results in decreased activity of HRH1 protein |
CTD |
PMID:2864258 |
|
NCBI chr 4:149,120,511...149,204,267
|
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
increases metabolic processing |
ISO |
CYP2B6 protein results in increased metabolism of Benzphetamine |
CTD |
PMID:12464242 PMID:15769884 |
|
NCBI chr 1:90,780,468...90,859,852
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
Benzphetamine inhibits the reaction [CYP3A4 protein results in increased oxidation of 7-benzyloxy-4-trifluoromethylcoumarin] |
CTD |
PMID:19299527 |
|
NCBI chr12:14,321,771...14,343,886
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions |
ISO |
Bepridil inhibits the reaction [ABCB1 protein results in increased transport of Digoxin] |
CTD |
PMID:11895100 |
|
NCBI chr 4:26,312,403...26,488,456
|
|
G |
Atf4 |
activating transcription factor 4 |
increases expression |
ISO |
Bepridil results in increased expression of ATF4 protein |
CTD |
PMID:21292685 |
|
NCBI chr 7:113,684,681...113,686,739
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
affects metabolic processing |
ISO |
CYP3A4 protein affects the metabolism of Bepridil |
CTD |
PMID:15286053 |
|
NCBI chr12:14,321,771...14,343,886
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression |
ISO |
Bepridil results in increased expression of DDIT3 protein |
CTD |
PMID:21292685 |
|
NCBI chr 7:65,001,695...65,006,517
|
|
G |
Eif2a |
eukaryotic translation initiation factor 2A |
increases phosphorylation |
ISO |
Bepridil results in increased phosphorylation of EIF2A protein |
CTD |
PMID:21292685 |
|
NCBI chr 2:142,761,303...142,794,767
|
|
G |
Kcna5 |
potassium voltage-gated channel subfamily A member 5 |
decreases activity |
ISO |
Bepridil results in decreased activity of KCNA5 protein |
CTD |
PMID:11711026 |
|
NCBI chr 4:161,040,853...161,044,311
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
multiple interactions decreases activity |
ISO |
Bepridil binds to and results in decreased activity of KCNH2 protein; Bepridil inhibits the reaction [KCNH2 protein results in increased transport of Thallium] Bepridil results in decreased activity of KCNH2 protein |
CTD |
PMID:15272206 PMID:15671647 PMID:21158687 PMID:24052561 |
|
NCBI chr 4:11,719,357...11,751,424
|
|
G |
Slc8a1 |
solute carrier family 8 member A1 |
multiple interactions |
ISO |
Bepridil inhibits the reaction [SLC8A1 protein results in increased susceptibility to Chlorodiphenyl (54% Chlorine)] |
CTD |
PMID:16009740 |
|
NCBI chr 6:13,194,609...13,547,369
|
|
G |
Tnfsf10 |
TNF superfamily member 10 |
increases response to substance |
ISO |
Bepridil results in increased susceptibility to TNFSF10 protein |
CTD |
PMID:21292685 |
|
NCBI chr 2:112,136,550...112,155,903
|
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
ISO |
butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA] |
CTD |
PMID:23688403 |
|
NCBI chr10:68,820,330...68,824,906
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
multiple interactions |
ISO |
4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [butenafine inhibits the reaction [Biological Products results in increased expression of CXCL10 protein]]; butenafine inhibits the reaction [Biological Products results in increased expression of CXCL10 mRNA]; butenafine inhibits the reaction [Biological Products results in increased expression of CXCL10 protein] |
CTD |
PMID:24471457 |
|
NCBI chr14:15,989,066...15,991,263
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
ISO |
4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CXCL8 mRNA]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Thromboxane B2]; butenafine promotes the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Dinoprostone] |
CTD |
PMID:23688403 |
|
NCBI chr10:38,272,003...38,277,549
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein] |
CTD |
PMID:23688403 |
|
NCBI chr 6:78,593,844...78,597,307
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
butenafine inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:50,668,817...50,711,019
|
|
G |
Stat1 |
signal transducer and activator of transcription 1 |
multiple interactions |
ISO |
4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [butenafine inhibits the reaction [Biological Products results in increased activity of STAT1 protein]]; butenafine inhibits the reaction [Biological Products results in increased phosphorylation of and results in increased activity of STAT1 protein] |
CTD |
PMID:24471457 |
|
NCBI chr 9:56,911,522...56,951,926
|
|
G |
Tslp |
thymic stromal lymphopoietin |
multiple interactions |
ISO |
4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein] |
CTD |
PMID:23688403 |
|
NCBI chr18:24,723,990...24,728,419
|
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions |
ISO |
chloroprocaine results in increased expression of BAX protein LINC00494 inhibits the reaction [chloroprocaine results in increased expression of BAX protein] |
CTD |
PMID:37650745 |
|
NCBI chr 1:105,076,472...105,081,906
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression multiple interactions |
ISO |
chloroprocaine results in decreased expression of CCND1 protein LINC00494 inhibits the reaction [chloroprocaine results in decreased expression of CCND1 protein] |
CTD |
PMID:37650745 |
|
NCBI chr 1:209,518,288...209,527,986
|
|
G |
Med19 |
mediator complex subunit 19 |
decreases expression multiple interactions |
ISO |
chloroprocaine results in decreased expression of MED19 mRNA; chloroprocaine results in decreased expression of MED19 protein LINC00494 inhibits the reaction [chloroprocaine results in decreased expression of MED19 mRNA]; LINC00494 inhibits the reaction [chloroprocaine results in decreased expression of MED19 protein] |
CTD |
PMID:37650745 |
|
NCBI chr 3:69,762,138...69,772,661
|
|
G |
Pcna |
proliferating cell nuclear antigen |
decreases expression multiple interactions |
ISO |
chloroprocaine results in decreased expression of PCNA protein LINC00494 inhibits the reaction [chloroprocaine results in decreased expression of PCNA protein] |
CTD |
PMID:37650745 |
|
NCBI chr 3:139,951,948...139,955,820
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions decreases expression |
ISO EXP |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of ABCB11 mRNA Chlorpromazine results in decreased expression of ABCB11 mRNA; Chlorpromazine results in decreased expression of ABCB11 protein |
CTD |
PMID:27344345 PMID:27765674 PMID:28391356 PMID:35708773 |
|
NCBI chr 3:74,424,620...74,520,646
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases expression decreases activity |
ISO |
Chlorpromazine analog results in increased expression of ABCB1 mRNA Chlorpromazine results in decreased activity of ABCB1 protein |
CTD |
PMID:15924885 PMID:16810505 |
|
NCBI chr 4:26,312,403...26,488,456
|
|
G |
Abcb1b |
ATP-binding cassette, sub-family B member 1B |
affects activity |
EXP |
Chlorpromazine affects the activity of ABCB1B protein |
CTD |
PMID:12626638 |
|
NCBI chr 4:26,197,706...26,280,156
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of ABCB4 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr 4:26,106,895...26,164,440
|
|
G |
Abcb6 |
ATP binding cassette subfamily B member 6 |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of ABCB6 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 9:84,117,222...84,125,939
|
|
G |
Abcb9 |
ATP binding cassette subfamily B member 9 |
increases expression |
EXP |
Chlorpromazine results in increased expression of ABCB9 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr12:32,499,213...32,531,932
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
increases expression multiple interactions |
EXP ISO |
Chlorpromazine results in increased expression of ABCC2 mRNA [Bile Acids and Salts co-treated with Chlorpromazine] results in decreased expression of ABCC2 mRNA |
CTD |
PMID:27765674 PMID:35708773 |
|
NCBI chr 1:252,613,875...252,672,459
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
increases expression multiple interactions decreases expression |
ISO EXP |
Chlorpromazine analog results in increased expression of ABCC3 mRNA [Bile Acids and Salts co-treated with Chlorpromazine] results in decreased expression of ABCC3 mRNA Chlorpromazine results in decreased expression of ABCC3 mRNA |
CTD |
PMID:15924885 PMID:25596134 PMID:35708773 |
|
NCBI chr10:79,793,571...79,839,528
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
increases expression |
ISO |
Chlorpromazine results in increased expression of ABCC4 mRNA |
CTD |
PMID:35708773 |
|
NCBI chr15:101,948,387...102,182,912
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions |
ISO |
Chlorpromazine inhibits the reaction [ABCG2 protein results in increased transport of Mitoxantrone] |
CTD |
PMID:18834354 |
|
NCBI chr 4:89,006,056...89,132,915
|
|
G |
Abcg8 |
ATP binding cassette subfamily G member 8 |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of ABCG8 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr 6:9,945,629...9,964,912
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
decreases phosphorylation |
EXP |
Chlorpromazine results in decreased phosphorylation of ACACA protein |
CTD |
PMID:17512020 |
|
NCBI chr10:69,511,627...69,773,888
|
|
G |
Ace2 |
angiotensin converting enzyme 2 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of ACE2 mRNA |
CTD |
PMID:32808185 |
|
NCBI chr X:30,293,597...30,340,961
|
|
G |
Ache |
acetylcholinesterase |
decreases activity increases activity multiple interactions |
ISO |
Chlorpromazine results in decreased activity of ACHE protein Chlorpromazine results in increased activity of ACHE protein Dichlorvos promotes the reaction [Chlorpromazine results in decreased activity of ACHE protein] |
CTD |
PMID:4859365 PMID:29614332 |
|
NCBI chr12:25,042,882...25,050,608
|
|
G |
Acp5 |
acid phosphatase 5, tartrate resistant |
multiple interactions |
ISO |
Chlorpromazine inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 mRNA] |
CTD |
PMID:21869564 |
|
NCBI chr 8:28,939,984...28,946,639
|
|
G |
Adra1a |
adrenoceptor alpha 1A |
decreases activity |
EXP |
Chlorpromazine results in decreased activity of ADRA1A protein |
CTD |
PMID:23611293 |
|
NCBI chr15:45,005,648...45,111,416
|
|
G |
Adra1b |
adrenoceptor alpha 1B |
decreases activity |
EXP |
Chlorpromazine results in decreased activity of ADRA1B protein |
CTD |
PMID:23611293 |
|
NCBI chr10:28,255,025...28,373,418
|
|
G |
Afp |
alpha-fetoprotein |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of AFP mRNA |
CTD |
PMID:15924885 |
|
NCBI chr14:17,573,412...17,591,476
|
|
G |
Agrn |
agrin |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of AGRN mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 5:172,031,528...172,064,429
|
|
G |
Ahr |
aryl hydrocarbon receptor |
affects activity |
EXP |
Chlorpromazine affects the activity of AHR protein |
CTD |
PMID:25596134 |
|
NCBI chr 6:57,961,423...57,998,901
|
|
G |
Ak3 |
adenylate kinase 3 |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of AK3 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 1:236,151,012...236,178,689
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases phosphorylation |
EXP |
Chlorpromazine results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:17512020 |
|
NCBI chr 6:137,534,810...137,555,131
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of ALDH1A1 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr 1:218,000,470...218,152,962
|
|
G |
Aldoa |
aldolase, fructose-bisphosphate A |
increases expression |
EXP |
Chlorpromazine results in increased expression of ALDOA mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 1:181,402,275...181,407,476
|
|
G |
Alpp |
alkaline phosphatase, placental |
multiple interactions |
ISO |
Chlorpromazine inhibits the reaction [Colforsin results in increased expression of ALPP mRNA]; Chlorpromazine inhibits the reaction [Isoproterenol results in increased expression of ALPP mRNA] |
CTD |
PMID:16036225 |
|
NCBI chr 9:95,213,763...95,216,509
|
|
G |
Ap1s1 |
adaptor related protein complex 1 subunit sigma 1 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of AP1S1 mRNA |
CTD |
PMID:17175557 |
|
NCBI chr12:19,625,267...19,635,792
|
|
G |
Apoc4 |
apolipoprotein C4 |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of APOC4 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr 1:79,335,745...79,339,942
|
|
G |
Apof |
apolipoprotein F |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of APOF mRNA |
CTD |
PMID:27344345 |
|
NCBI chr 7:700,688...702,130
|
|
G |
Areg |
amphiregulin |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of AREG mRNA |
CTD |
PMID:15924885 PMID:30703373 |
|
NCBI chr14:17,256,384...17,265,641
|
|
G |
Arfgef2 |
ARF guanine nucleotide exchange factor 2 |
increases expression |
EXP |
Chlorpromazine results in increased expression of ARFGEF2 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 3:155,547,504...155,633,652
|
|
G |
Arhgef10 |
Rho guanine nucleotide exchange factor 10 |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of ARHGEF10 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr16:74,647,147...74,738,784
|
|
G |
Asah1 |
N-acylsphingosine amidohydrolase 1 |
increases expression |
ISO |
Chlorpromazine results in increased expression of ASAH1 mRNA |
CTD |
PMID:17175557 |
|
NCBI chr16:57,669,927...57,701,349
|
|
G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
increases expression |
ISO |
Chlorpromazine results in increased expression of ASNS mRNA |
CTD |
PMID:17175557 |
|
NCBI chr 4:36,752,061...36,769,970
|
|
G |
Atf4 |
activating transcription factor 4 |
affects activity multiple interactions |
EXP ISO |
Chlorpromazine affects the activity of ATF4 protein [Chlorpromazine co-treated with Cholic Acids] affects the expression of ATF4 mRNA |
CTD |
PMID:25596134 PMID:27344345 |
|
NCBI chr 7:113,684,681...113,686,739
|
|
G |
Atp6v1b2 |
ATPase H+ transporting V1 subunit B2 |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of ATP6V1B2 protein |
CTD |
PMID:19441803 |
|
NCBI chr16:20,617,515...20,641,651
|
|
G |
Avp |
arginine vasopressin |
increases expression multiple interactions |
ISO EXP |
Chlorpromazine results in increased expression of AVP protein Chlorpromazine inhibits the reaction [Lithium results in increased expression of AVP protein] |
CTD |
PMID:3567260 PMID:3976404 |
|
NCBI chr 3:138,246,544...138,248,522
|
|
G |
Bag4 |
BAG cochaperone 4 |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of BAG4 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr16:66,288,678...66,305,893
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
increases expression |
ISO |
Chlorpromazine results in increased expression of BCL2L1 mRNA |
CTD |
PMID:21683644 |
|
NCBI chr 3:161,713,777...161,764,844
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
affects response to substance affects expression |
ISO EXP |
BDNF affects the susceptibility to Chlorpromazine Chlorpromazine affects the expression of BDNF mRNA |
CTD |
PMID:18408624 PMID:31324950 |
|
NCBI chr 3:116,619,633...116,670,212
|
|
G |
Bhlhe40 |
basic helix-loop-helix family, member e40 |
increases expression |
ISO |
Chlorpromazine analog results in increased expression of BHLHE40 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 4:141,618,453...141,624,154
|
|
G |
Birc2 |
baculoviral IAP repeat-containing 2 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of BIRC2 mRNA |
CTD |
PMID:30703373 |
|
NCBI chr 8:13,253,697...13,273,672
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of BIRC5 mRNA; Chlorpromazine results in decreased expression of BIRC5 mRNA |
CTD |
PMID:15924885 PMID:30703373 |
|
NCBI chr10:103,567,369...103,580,069
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
increases expression |
EXP |
Chlorpromazine results in increased expression of BNIP3 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 1:203,137,778...203,154,962
|
|
G |
Btg2 |
BTG anti-proliferation factor 2 |
increases expression |
ISO |
Chlorpromazine analog results in increased expression of BTG2 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr13:48,083,931...48,087,690
|
|
G |
Btg3 |
BTG anti-proliferation factor 3 |
increases expression |
ISO |
Chlorpromazine analog results in increased expression of BTG3 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr11:17,030,156...17,046,069
|
|
G |
C3 |
complement C3 |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of C3 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr 9:2,174,412...2,201,339
|
|
G |
C6 |
complement C6 |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of C6 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr 2:53,846,028...53,921,279
|
|
G |
Calcr |
calcitonin receptor |
multiple interactions |
ISO |
Chlorpromazine inhibits the reaction [TNFSF11 protein results in increased expression of CALCR mRNA] |
CTD |
PMID:21869564 |
|
NCBI chr 4:31,661,270...31,736,392
|
|
G |
Calr |
calreticulin |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of CALR mRNA |
CTD |
PMID:18246545 |
|
NCBI chr19:40,213,367...40,218,262
|
|
G |
Car2 |
carbonic anhydrase 2 |
multiple interactions |
ISO |
Chlorpromazine inhibits the reaction [TNFSF11 protein results in increased expression of CAR2 mRNA] |
CTD |
PMID:21869564 |
|
NCBI chr 2:88,462,883...88,478,012
|
|
G |
Cat |
catalase |
multiple interactions decreases expression decreases activity |
EXP ISO |
carvedilol inhibits the reaction [Chlorpromazine results in decreased expression of CAT protein]; zolpidem inhibits the reaction [Chlorpromazine results in decreased activity of CAT] |
CTD |
PMID:12010767 PMID:17513028 PMID:25449126 |
|
NCBI chr 3:110,297,340...110,329,526
|
|
G |
Ccn2 |
cellular communication network factor 2 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of CCN2 mRNA; Chlorpromazine results in decreased expression of CCN2 protein |
CTD |
PMID:30703373 |
|
NCBI chr 1:22,621,498...22,624,614
|
|
G |
Ccn3 |
cellular communication network factor 3 |
affects expression |
EXP |
Chlorpromazine affects the expression of CCN3 mRNA |
CTD |
PMID:31324950 |
|
NCBI chr 7:87,983,788...87,990,810
|
|
G |
Ccnb2 |
cyclin B2 |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of CCNB2 mRNA; Chlorpromazine results in decreased expression of CCNB2 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 8:79,968,459...79,981,717
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of CCND1 mRNA |
CTD |
PMID:17202759 |
|
NCBI chr 1:209,518,288...209,527,986
|
|
G |
Ccnd3 |
cyclin D3 |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of CCND3 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 9:20,891,696...20,987,199
|
|
G |
Ccnf |
cyclin F |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of CCNF mRNA |
CTD |
PMID:15924885 |
|
NCBI chr10:13,757,884...13,783,669
|
|
G |
Cd274 |
CD274 molecule |
multiple interactions |
ISO |
Chlorpromazine inhibits the reaction [platycodin D results in decreased expression of and results in increased secretion of CD274 protein] |
CTD |
PMID:31150782 |
|
NCBI chr 1:236,526,215...236,549,956
|
|
G |
Cd44 |
CD44 molecule |
multiple interactions decreases expression |
ISO |
Chlorpromazine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of CD44 protein] Chlorpromazine results in decreased expression of CD44 protein |
CTD |
PMID:9929743 PMID:30703373 |
|
NCBI chr 3:109,610,824...109,699,776
|
|
G |
Cd86 |
CD86 molecule |
increases expression |
ISO |
Chlorpromazine results in increased expression of CD86 protein |
CTD |
PMID:19665512 |
|
NCBI chr11:77,647,565...77,706,178
|
|
G |
Cdk5 |
cyclin-dependent kinase 5 |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of CDK5 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 4:11,647,098...11,651,606
|
|
G |
Cdk7 |
cyclin-dependent kinase 7 |
increases expression |
ISO |
Chlorpromazine analog results in increased expression of CDK7 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 2:33,574,623...33,599,485
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions increases expression |
EXP |
[EGR1 binds to CDKN1A promoter] promotes the reaction [Chlorpromazine results in increased expression of CDKN1A mRNA]; EGR1 promotes the reaction [Chlorpromazine results in increased expression of CDKN1A mRNA] |
CTD |
PMID:20368687 |
|
NCBI chr20:7,150,820...7,161,373
|
|
G |
Cdkn2c |
cyclin-dependent kinase inhibitor 2C |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of CDKN2C mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 5:129,639,736...129,645,564
|
|
G |
Ces2h |
carboxylesterase 2H |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of CES2 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr19:32,974,242...32,988,842
|
|
G |
Cfh |
complement factor H |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of CFH mRNA |
CTD |
PMID:27344345 |
|
NCBI chr13:51,512,376...51,613,829
|
|
G |
Cgref1 |
cell growth regulator with EF hand domain 1 |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of CGREF1 mRNA |
CTD |
PMID:17202759 |
|
NCBI chr 6:25,431,846...25,443,853
|
|
G |
Chtf18 |
chromosome transmission fidelity factor 18 |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of CHTF18 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr10:15,247,525...15,255,573
|
|
G |
Cited2 |
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of CITED2 mRNA |
CTD |
PMID:18246545 |
|
NCBI chr 1:12,312,426...12,314,869
|
|
G |
Cks2 |
CDC28 protein kinase regulatory subunit 2 |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of CKS2 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr17:13,570,611...13,575,770
|
|
G |
Clcf1 |
cardiotrophin-like cytokine factor 1 |
increases expression |
ISO |
Chlorpromazine results in increased expression of CLCF1 mRNA |
CTD |
PMID:21683644 |
|
NCBI chr 1:201,507,763...201,517,607
|
|
G |
Col18a1 |
collagen type XVIII alpha 1 chain |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of COL18A1 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr20:11,474,104...11,582,593
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
increases expression |
ISO |
Chlorpromazine results in increased expression of COL1A1 mRNA |
CTD |
PMID:35708773 |
|
NCBI chr10:80,380,458...80,397,461
|
|
G |
Col4a1 |
collagen type IV alpha 1 chain |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of COL4A1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr16:84,885,597...84,996,482
|
|
G |
Cort |
cortistatin |
affects expression |
EXP |
Chlorpromazine affects the expression of CORT mRNA |
CTD |
PMID:31324950 |
|
NCBI chr 5:159,560,591...159,562,032
|
|
G |
Cox8a |
cytochrome c oxidase subunit 8A |
affects expression increases expression |
EXP |
Chlorpromazine affects the expression of COX8A mRNA Chlorpromazine results in increased expression of COX8A mRNA |
CTD |
PMID:18246545 |
|
NCBI chr 1:213,831,302...213,833,623
|
|
G |
Crh |
corticotropin releasing hormone |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of CRH mRNA |
CTD |
PMID:16205782 |
|
NCBI chr 2:104,059,184...104,061,048
|
|
G |
Cth |
cystathionine gamma-lyase |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of CTH mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 2:249,634,731...249,661,066
|
|
G |
Ctsk |
cathepsin K |
multiple interactions |
ISO |
Chlorpromazine inhibits the reaction [TNFSF11 protein results in increased expression of CTSK mRNA] |
CTD |
PMID:21869564 |
|
NCBI chr 2:185,747,548...185,758,512
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions decreases activity decreases response to substance increases expression |
ISO EXP |
[Filipin co-treated with Chlorpromazine co-treated with Wortmannin] inhibits the reaction [Particulate Matter results in increased expression of CYP1A1 mRNA]; Chlorpromazine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein] Chlorpromazine results in decreased activity of CYP1A1 protein CYP1A1 protein results in decreased susceptibility to Chlorpromazine Chlorpromazine results in increased expression of CYP1A1 mRNA |
CTD |
PMID:17202759 PMID:18246545 PMID:18493746 PMID:25596134 PMID:26477383 PMID:29724254 PMID:33814510 More...
|
|
NCBI chr 8:66,991,940...66,998,014
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions decreases response to substance increases expression increases oxidation affects expression decreases methylation |
ISO EXP |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of CYP1A2 mRNA; [CYP1A2 protein co-treated with CYP2C9 protein co-treated with CYP3A4 protein co-treated with CYP2D6 protein co-treated with CYP2C19 protein] affects the susceptibility to Chlorpromazine; Chlorpromazine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A2 protein]; CYP1A2 protein results in increased metabolism of and results in increased activity of Chlorpromazine CYP1A2 protein results in decreased susceptibility to Chlorpromazine Chlorpromazine results in increased expression of CYP1A2 mRNA CYP1A2 protein results in increased oxidation of Chlorpromazine Chlorpromazine affects the expression of CYP1A2 mRNA CYP1A2 protein results in decreased methylation of Chlorpromazine |
CTD |
PMID:18246545 PMID:18493746 PMID:19482014 PMID:20615392 PMID:23397584 PMID:25596134 PMID:26477383 PMID:27344345 More...
|
|
NCBI chr 8:66,971,261...66,978,149
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases response to substance decreases activity multiple interactions |
ISO |
CYP1B1 protein results in decreased susceptibility to Chlorpromazine Chlorpromazine results in decreased activity of CYP1B1 protein [Filipin co-treated with Chlorpromazine co-treated with Wortmannin] inhibits the reaction [Particulate Matter results in increased expression of CYP1B1 mRNA] |
CTD |
PMID:26477383 PMID:29724254 PMID:33814510 |
|
NCBI chr 6:21,093,927...21,103,091
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
multiple interactions decreases response to substance |
ISO |
[Chlorpromazine results in increased activity of NR1I3 protein alternative form] which results in increased expression of CYP2B6 mRNA; Chlorpromazine inhibits the reaction [Androstenols inhibits the reaction [NR1I3 protein results in increased expression of CYP2B6 mRNA]] NR1I3 protein affects the reaction [Chlorpromazine results in increased expression of CYP2B10 mRNA] CYP2B6 protein results in decreased susceptibility to Chlorpromazine |
CTD |
PMID:10037683 PMID:12049174 PMID:17041008 PMID:26477383 |
|
NCBI chr 1:90,780,468...90,859,852
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
decreases expression decreases response to substance |
EXP ISO |
Chlorpromazine results in decreased expression of CYP2C mRNA; Chlorpromazine results in decreased expression of CYP2C11 mRNA CYP2C18 protein results in decreased susceptibility to Chlorpromazine |
CTD |
PMID:18246545 PMID:26477383 |
|
NCBI chr 1:246,175,216...246,211,445
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
multiple interactions decreases response to substance decreases activity affects methylation |
ISO |
[CYP1A2 protein co-treated with CYP2C9 protein co-treated with CYP3A4 protein co-treated with CYP2D6 protein co-treated with CYP2C19 protein] affects the susceptibility to Chlorpromazine CYP2C19 protein results in decreased susceptibility to Chlorpromazine Chlorpromazine results in decreased activity of CYP2C19 protein CYP2C19 protein affects the methylation of Chlorpromazine |
CTD |
PMID:15135088 PMID:20615392 PMID:23397584 PMID:26477383 |
|
NCBI chr 1:247,879,058...247,916,804
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
decreases response to substance |
ISO |
CYP2C8 protein results in decreased susceptibility to Chlorpromazine |
CTD |
PMID:26477383 |
|
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
multiple interactions decreases response to substance |
ISO |
[CYP1A2 protein co-treated with CYP2C9 protein co-treated with CYP3A4 protein co-treated with CYP2D6 protein co-treated with CYP2C19 protein] affects the susceptibility to Chlorpromazine; CYP2D6 protein results in increased metabolism of and results in increased activity of Chlorpromazine CYP2D6 protein results in decreased susceptibility to Chlorpromazine |
CTD |
PMID:19482014 PMID:23397584 PMID:26477383 |
|
NCBI chr 7:115,762,662...115,771,832
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
decreases activity decreases response to substance |
ISO |
Chlorpromazine results in decreased activity of CYP2E1 protein CYP2E1 protein results in decreased susceptibility to Chlorpromazine |
CTD |
PMID:15135088 PMID:26477383 |
|
NCBI chr 1:205,269,967...205,280,365
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
affects methylation affects oxidation multiple interactions decreases response to substance decreases activity |
ISO |
CYP3A4 protein affects the methylation of Chlorpromazine CYP3A4 protein affects the oxidation of Chlorpromazine [Chlorpromazine results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; [CYP1A2 protein co-treated with CYP2C9 protein co-treated with CYP3A4 protein co-treated with CYP2D6 protein co-treated with CYP2C19 protein] affects the susceptibility to Chlorpromazine CYP3A4 protein results in decreased susceptibility to Chlorpromazine Chlorpromazine results in decreased activity of CYP3A4 protein |
CTD |
PMID:15135088 PMID:17041008 PMID:20615392 PMID:23397584 PMID:26477383 |
|
NCBI chr12:14,321,771...14,343,886
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
decreases response to substance |
ISO |
CYP3A5 protein results in decreased susceptibility to Chlorpromazine |
CTD |
PMID:26477383 |
|
NCBI chr12:21,919,955...21,960,160
|
|
G |
Cyp8b1 |
cytochrome P450 family 8 subfamily B member 1 |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of CYP8B1 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr 8:130,455,622...130,457,592
|
|
G |
Dao |
D-amino-acid oxidase |
decreases activity |
ISO |
Chlorpromazine results in decreased activity of DAO protein |
CTD |
PMID:18615285 |
|
NCBI chr12:42,592,342...42,613,046
|
|
G |
Dcstamp |
dendrocyte expressed seven transmembrane protein |
multiple interactions |
ISO |
Chlorpromazine inhibits the reaction [TNFSF11 protein results in increased expression of DCSTAMP mRNA] |
CTD |
PMID:21869564 |
|
NCBI chr 7:70,807,455...70,822,067
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression |
EXP |
Chlorpromazine results in increased expression of DDIT3 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 7:65,001,695...65,006,517
|
|
G |
Depp1 |
DEPP autophagy regulator 1 |
increases expression |
ISO |
Chlorpromazine results in increased expression of DEPP1 mRNA |
CTD |
PMID:15342952 PMID:17175557 |
|
NCBI chr 4:149,910,794...149,913,013
|
|
G |
Drd1 |
dopamine receptor D1 |
decreases activity |
ISO |
Chlorpromazine results in decreased activity of DRD1 protein |
CTD |
PMID:23611293 |
|
NCBI chr17:10,545,488...10,550,029
|
|
G |
Drd2 |
dopamine receptor D2 |
decreases response to substance decreases activity |
ISO |
DRD2 polymorphism results in decreased susceptibility to Chlorpromazine Chlorpromazine results in decreased activity of DRD2 protein |
CTD |
PMID:15694263 PMID:23611293 |
|
NCBI chr 8:58,605,403...58,669,339
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
increases expression affects expression |
ISO |
Chlorpromazine analog results in increased expression of DUSP1 mRNA Chlorpromazine affects the expression of DUSP1 mRNA |
CTD |
PMID:15924885 PMID:20843724 |
|
NCBI chr10:17,184,853...17,187,646
|
|
G |
Dusp9 |
dual specificity phosphatase 9 |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of DUSP9 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr X:151,351,897...151,355,822
|
|
G |
E2f1 |
E2F transcription factor 1 |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of E2F1 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 3:163,524,739...163,535,563
|
|
G |
Egr1 |
early growth response 1 |
increases expression multiple interactions |
EXP |
Chlorpromazine results in increased expression of EGR1 [EGR1 binds to CDKN1A promoter] promotes the reaction [Chlorpromazine results in increased expression of CDKN1A mRNA]; EGR1 promotes the reaction [Chlorpromazine results in increased expression of CDKN1A mRNA]; MAPK1 affects the reaction [Chlorpromazine results in increased expression of EGR1]; MAPK3 affects the reaction [Chlorpromazine results in increased expression of EGR1] |
CTD |
PMID:20368687 |
|
NCBI chr18:26,737,078...26,740,877
|
|
G |
Eif1 |
eukaryotic translation initiation factor 1 |
increases expression |
EXP |
Chlorpromazine results in increased expression of EIF1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr10:85,747,064...85,749,447
|
|
G |
Eno2 |
enolase 2 |
increases expression |
EXP |
Chlorpromazine results in increased expression of ENO2 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 4:159,258,371...159,267,220
|
|
G |
Ero1a |
endoplasmic reticulum oxidoreductase 1 alpha |
increases expression |
EXP |
Chlorpromazine results in increased expression of ERO1A mRNA |
CTD |
PMID:25596134 |
|
NCBI chr15:18,495,037...18,530,440
|
|
G |
F2 |
coagulation factor II, thrombin |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of F2 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 3:98,051,958...98,065,246
|
|
G |
Fabp1 |
fatty acid binding protein 1 |
increases expression |
ISO |
Chlorpromazine results in increased expression of FABP1 mRNA |
CTD |
PMID:15342952 PMID:17175557 |
|
NCBI chr 4:104,744,302...104,753,119
|
|
G |
Fas |
Fas cell surface death receptor |
increases expression |
ISO |
Chlorpromazine analog results in increased expression of FAS mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 1:241,212,155...241,245,774
|
|
G |
Fbp1 |
fructose-bisphosphatase 1 |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of FBP1 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr17:2,207,271...2,230,076
|
|
G |
Fbxo22 |
F-box protein 22 |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of FBXO22 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 8:64,476,034...64,492,063
|
|
G |
Fech |
ferrochelatase |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of FECH mRNA |
CTD |
PMID:25596134 |
|
NCBI chr18:57,945,123...57,978,327
|
|
G |
Fetub |
fetuin B |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of FETUB mRNA |
CTD |
PMID:27344345 |
|
NCBI chr11:78,082,158...78,093,022
|
|
G |
Fga |
fibrinogen alpha chain |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of FGA mRNA |
CTD |
PMID:27344345 |
|
NCBI chr 2:170,672,169...170,679,572
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of FGF2 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr 2:122,164,454...122,218,796
|
|
G |
Fgfr1 |
Fibroblast growth factor receptor 1 |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of FGFR1 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr16:73,194,631...73,249,855
|
|
G |
Fgr |
FGR proto-oncogene, Src family tyrosine kinase |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of FGR mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 5:150,473,767...150,503,524
|
|
G |
Fkbp5 |
FKBP prolyl isomerase 5 |
multiple interactions |
ISO |
Chlorpromazine inhibits the reaction [Lipopolysaccharides results in decreased expression of FKBP5 protein] |
CTD |
PMID:21034739 |
|
NCBI chr20:6,458,931...6,577,227
|
|
G |
Fndc4 |
fibronectin type III domain containing 4 |
increases expression |
ISO |
Chlorpromazine results in increased expression of FNDC4 mRNA |
CTD |
PMID:15342952 PMID:17175557 |
|
NCBI chr 6:25,077,155...25,080,812
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
affects expression |
ISO |
Chlorpromazine affects the expression of FOS mRNA |
CTD |
PMID:20843724 |
|
NCBI chr 6:110,852,188...110,855,054
|
|
G |
Fosb |
FosB proto-oncogene, AP-1 transcription factor subunit |
affects expression |
ISO |
Chlorpromazine affects the expression of FOSB mRNA |
CTD |
PMID:20843724 |
|
NCBI chr 1:88,082,324...88,089,506
|
|
G |
Fosl1 |
FOS like 1, AP-1 transcription factor subunit |
increases expression affects expression |
ISO |
Chlorpromazine analog results in increased expression of FOSL1 mRNA Chlorpromazine affects the expression of FOSL1 mRNA |
CTD |
PMID:15924885 PMID:20843724 |
|
NCBI chr 1:212,183,885...212,192,391
|
|
G |
Fosl2 |
FOS like 2, AP-1 transcription factor subunit |
affects expression |
ISO |
Chlorpromazine affects the expression of FOSL2 mRNA |
CTD |
PMID:20843724 |
|
NCBI chr 6:30,017,952...30,039,269
|
|
G |
Fth1 |
ferritin heavy chain 1 |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of FTH1 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr 1:216,052,037...216,054,325
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
decreases expression decreases activity multiple interactions |
ISO EXP |
Chlorpromazine analog results in decreased expression of G6PD mRNA Chlorpromazine results in decreased activity of G6PD protein [Taurine co-treated with coenzyme Q10] inhibits the reaction [Chlorpromazine results in decreased activity of G6PD protein]; coenzyme Q10 inhibits the reaction [Chlorpromazine results in decreased activity of G6PD protein]; Taurine inhibits the reaction [Chlorpromazine results in decreased activity of G6PD protein] |
CTD |
PMID:15924885 PMID:33548410 |
|
NCBI chr X:157,352,364...157,372,144
|
|
G |
Gad1 |
glutamate decarboxylase 1 |
decreases methylation multiple interactions |
ISO |
Chlorpromazine results in decreased methylation of GAD1 promoter Valproic Acid promotes the reaction [Chlorpromazine results in decreased methylation of GAD1 promoter] |
CTD |
PMID:19110320 |
|
NCBI chr 3:75,777,260...75,818,099
|
|
G |
Gcgr |
glucagon receptor |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of GCGR mRNA |
CTD |
PMID:27344345 |
|
NCBI chr10:106,306,803...106,314,970
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of GCLC mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 8:87,510,251...87,548,896
|
|
G |
Gdf15 |
growth differentiation factor 15 |
increases expression |
EXP |
Chlorpromazine results in increased expression of GDF15 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr16:18,838,436...18,842,022
|
|
G |
Gdpd3 |
glycerophosphodiester phosphodiesterase domain containing 3 |
increases expression |
ISO |
Chlorpromazine results in increased expression of GDPD3 mRNA |
CTD |
PMID:15342952 PMID:17175557 |
|
NCBI chr 1:181,373,505...181,383,063
|
|
G |
Gfap |
glial fibrillary acidic protein |
affects expression |
EXP |
Chlorpromazine affects the expression of GFAP mRNA |
CTD |
PMID:31324950 |
|
NCBI chr10:88,352,987...88,361,661
|
|
G |
Gpnmb |
glycoprotein nmb |
increases expression |
EXP |
Chlorpromazine results in increased expression of GPNMB mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 4:79,341,128...79,362,366
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
increases expression |
EXP |
Chlorpromazine results in increased expression of GPT protein |
CTD |
PMID:35722787 |
|
NCBI chr 7:110,295,599...110,300,134
|
|
G |
Gsr |
glutathione-disulfide reductase |
decreases activity |
EXP |
Chlorpromazine results in decreased activity of GSR protein |
CTD |
PMID:6693892 |
|
NCBI chr16:65,185,574...65,228,742
|
|
G |
Gsta1 |
glutathione S-transferase alpha 1 |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of GSTA1 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr 9:23,703,476...23,720,121
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
affects activity |
EXP |
Chlorpromazine affects the activity of HIF1A protein |
CTD |
PMID:25596134 |
|
NCBI chr 6:98,357,788...98,405,068
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
increases expression |
ISO |
Chlorpromazine results in increased expression of HMGCR mRNA |
CTD |
PMID:17052361 |
|
NCBI chr 2:29,732,163...29,754,276
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
increases expression |
ISO |
Chlorpromazine results in increased expression of HMGCS1 mRNA |
CTD |
PMID:17052361 |
|
NCBI chr 2:53,379,457...53,399,807
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression affects expression |
ISO EXP |
Chlorpromazine results in increased expression of HMOX1 mRNA Chlorpromazine affects the expression of HMOX1 mRNA |
CTD |
PMID:15924885 PMID:25596134 PMID:31324950 |
|
NCBI chr19:13,452,365...13,479,823
|
|
G |
Hpn |
hepsin |
increases expression |
ISO |
Chlorpromazine results in increased expression of HPN mRNA |
CTD |
PMID:15342952 PMID:17175557 |
|
NCBI chr 1:86,337,085...86,352,785
|
|
G |
Hspa2 |
heat shock protein family A (Hsp70) member 2 |
increases expression decreases expression |
EXP |
Chlorpromazine results in increased expression of HSPA2 mRNA Chlorpromazine results in decreased expression of HSPA2 mRNA; Chlorpromazine results in decreased expression of HSPA2 protein |
CTD |
PMID:36751017 |
|
NCBI chr 6:100,864,172...100,866,946
|
|
G |
Hspb1 |
heat shock protein family B (small) member 1 |
increases expression decreases expression |
EXP |
Chlorpromazine results in increased expression of HSPB1 mRNA Chlorpromazine results in decreased expression of HSPB1 mRNA |
CTD |
PMID:36751017 |
|
NCBI chr12:26,430,640...26,432,301
|
|
G |
Hspd1 |
heat shock protein family D (Hsp60) member 1 |
increases expression |
EXP |
Chlorpromazine results in increased expression of HSPD1 mRNA |
CTD |
PMID:36751017 |
|
NCBI chr 9:64,073,610...64,084,332
|
|
G |
Hspe1 |
heat shock protein family E (Hsp10) member 1 |
increases expression |
EXP |
Chlorpromazine results in increased expression of HSPE1 mRNA |
CTD |
PMID:36751017 |
|
NCBI chr 9:56,589,912...56,593,000
|
|
G |
Ibsp |
integrin-binding sialoprotein |
decreases expression multiple interactions |
EXP |
Chlorpromazine results in decreased expression of IBSP mRNA herbimycin inhibits the reaction [Chlorpromazine results in decreased expression of IBSP mRNA]; U 0126 inhibits the reaction [Chlorpromazine results in decreased expression of IBSP mRNA] |
CTD |
PMID:16294319 |
|
NCBI chr14:5,439,825...5,452,570
|
|
G |
Ifnb1 |
interferon beta 1 |
multiple interactions |
ISO |
Chlorpromazine promotes the reaction [PAM2-CSK4 results in increased expression of IFNB1 mRNA] |
CTD |
PMID:32796029 |
|
NCBI chr 5:108,066,650...108,067,487
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA |
CTD |
PMID:29594315 |
|
NCBI chr 7:55,789,180...55,793,216
|
|
G |
Ifnlr1 |
interferon, lambda receptor 1 |
increases expression |
ISO |
Chlorpromazine results in increased expression of IFNLR1 mRNA |
CTD |
PMID:21683644 |
|
NCBI chr 5:147,919,547...147,942,328
|
|
G |
Igfbp1 |
insulin-like growth factor binding protein 1 |
increases expression |
ISO |
Chlorpromazine results in increased expression of IGFBP1 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr14:86,261,277...86,266,344
|
|
G |
Ikbkg |
inhibitor of nuclear factor kappa B kinase regulatory subunit gamma |
increases expression |
ISO |
Chlorpromazine analog results in increased expression of IKBKG mRNA |
CTD |
PMID:15924885 |
|
NCBI chr X:157,358,279...157,397,563
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
ISO |
[IL6 protein co-treated with IL1A protein co-treated with TNF protein co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased susceptibility to Chlorpromazine |
CTD |
PMID:19362101 |
|
NCBI chr 3:136,979,804...136,990,236
|
|
G |
Il1b |
interleukin 1 beta |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of IL1B mRNA |
CTD |
PMID:29594315 |
|
NCBI chr 3:137,030,200...137,036,581
|
|
G |
Il2 |
interleukin 2 |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; Chlorpromazine inhibits the reaction [IL2 protein results in increased phosphorylation of MAPK1 protein]; Chlorpromazine inhibits the reaction [IL2 protein results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:11014349 PMID:29594315 |
|
NCBI chr 2:121,932,968...121,937,672
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
[IL6 protein co-treated with IL1A protein co-treated with TNF protein co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased susceptibility to Chlorpromazine |
CTD |
PMID:19362101 |
|
NCBI chr 4:5,889,999...5,894,575
|
|
G |
Inhbe |
inhibin subunit beta E |
increases expression |
ISO |
Chlorpromazine results in increased expression of INHBE mRNA |
CTD |
PMID:15342952 PMID:17175557 |
|
NCBI chr 7:65,061,531...65,064,519
|
|
G |
Ins1 |
insulin 1 |
decreases secretion |
EXP |
Chlorpromazine results in decreased secretion of INS1 protein |
CTD |
PMID:18308779 |
|
NCBI chr 1:261,186,119...261,186,686
|
|
G |
Insig2 |
insulin induced gene 2 |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of INSIG2 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr13:32,472,390...32,500,139
|
|
G |
Irs2 |
insulin receptor substrate 2 |
multiple interactions |
EXP |
Chlorpromazine results in decreased expression of and results in decreased phosphorylation of IRS2 protein; Chlorpromazine results in decreased expression of and results in increased degradation of IRS2 protein |
CTD |
PMID:17512020 PMID:18308779 |
|
NCBI chr16:85,190,310...85,214,543
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
multiple interactions decreases activity |
ISO |
Chlorpromazine inhibits the reaction [KCNH2 protein results in increased transport of Thallium] Chlorpromazine results in decreased activity of KCNH2 protein |
CTD |
PMID:15071359 PMID:21158687 PMID:24052561 |
|
NCBI chr 4:11,719,357...11,751,424
|
|
G |
Kcnn2 |
potassium calcium-activated channel subfamily N member 2 |
decreases activity |
EXP |
Chlorpromazine results in decreased activity of KCNN2 protein |
CTD |
PMID:10915830 |
|
NCBI chr18:40,004,693...40,445,043
|
|
G |
Klf4 |
KLF transcription factor 4 |
multiple interactions decreases expression |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of KLF4 mRNA Chlorpromazine results in decreased expression of KLF4 mRNA |
CTD |
PMID:27344345 PMID:30703373 |
|
NCBI chr 5:75,074,107...75,079,182
|
|
G |
Klkb1 |
kallikrein B1 |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of KLKB1 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr16:46,958,634...46,982,054
|
|
G |
Kng1 |
kininogen 1 |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of KNG1 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr11:77,812,757...77,835,555
|
|
G |
Lats1 |
large tumor suppressor kinase 1 |
increases phosphorylation |
ISO |
Chlorpromazine results in increased phosphorylation of LATS1 protein |
CTD |
PMID:30703373 |
|
NCBI chr 1:3,980,801...4,014,029
|
|
G |
Ldhc |
lactate dehydrogenase C |
decreases activity multiple interactions |
EXP |
Chlorpromazine results in decreased activity of LDHC protein [Taurine co-treated with coenzyme Q10] inhibits the reaction [Chlorpromazine results in decreased activity of LDHC protein]; coenzyme Q10 inhibits the reaction [Chlorpromazine results in decreased activity of LDHC protein]; Taurine inhibits the reaction [Chlorpromazine results in decreased activity of LDHC protein] |
CTD |
PMID:33548410 |
|
NCBI chr 1:97,385,984...97,403,382
|
|
G |
Ldlr |
low density lipoprotein receptor |
increases expression |
ISO |
Chlorpromazine results in increased expression of LDLR mRNA |
CTD |
PMID:17052361 |
|
NCBI chr 8:20,270,020...20,292,981
|
|
G |
Lep |
leptin |
increases expression |
EXP |
Chlorpromazine results in increased expression of LEP protein |
CTD |
PMID:17512020 |
|
NCBI chr 4:58,626,529...58,640,663
|
|
G |
Lss |
lanosterol synthase |
increases expression |
ISO |
Chlorpromazine results in increased expression of LSS mRNA |
CTD |
PMID:15342952 PMID:17175557 |
|
NCBI chr20:12,090,641...12,118,230
|
|
G |
Map2 |
microtubule-associated protein 2 |
increases expression |
EXP |
Chlorpromazine results in increased expression of MAP2 mRNA |
CTD |
PMID:15079866 |
|
NCBI chr 9:75,173,038...75,431,606
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO EXP |
Chlorpromazine inhibits the reaction [IL2 protein results in increased phosphorylation of MAPK1 protein] MAPK1 affects the reaction [Chlorpromazine results in increased expression of EGR1] |
CTD |
PMID:11014349 PMID:20368687 |
|
NCBI chr11:97,462,025...97,529,193
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of MAPK14 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr20:6,751,288...6,812,294
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
decreases expression multiple interactions |
ISO EXP |
Chlorpromazine analog results in decreased expression of MAPK3 mRNA MAPK3 affects the reaction [Chlorpromazine results in increased expression of EGR1] Chlorpromazine inhibits the reaction [IL2 protein results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:11014349 PMID:15924885 PMID:20368687 |
|
NCBI chr 1:190,797,189...190,803,411
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
[Chlorpromazine co-treated with lipoteichoic acid] results in increased phosphorylation of MAPK8 protein; Chlorpromazine promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of MAPK8 protein]; TIRAP gene mutant form inhibits the reaction [[Chlorpromazine co-treated with lipoteichoic acid] results in increased phosphorylation of MAPK8 protein]; TIRAP gene mutant form inhibits the reaction [Chlorpromazine promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of MAPK8 protein]] |
CTD |
PMID:23238562 |
|
NCBI chr16:8,645,171...8,728,225
|
|
G |
Mapkapk2 |
MAPK activated protein kinase 2 |
increases expression |
EXP |
Chlorpromazine results in increased expression of MAPKAPK2 mRNA |
CTD |
PMID:19441803 |
|
NCBI chr13:45,066,027...45,112,326
|
|
G |
Mcm3 |
minichromosome maintenance complex component 3 |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of MCM3 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 9:30,715,602...30,733,746
|
|
G |
Mcm5 |
minichromosome maintenance complex component 5 |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of MCM5 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr19:13,488,813...13,510,131
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
increases expression |
EXP |
Chlorpromazine results in increased expression of MDM2 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 7:55,176,558...55,201,757
|
|
G |
Mitf |
melanocyte inducing transcription factor |
increases expression |
ISO |
Chlorpromazine results in increased expression of MITF protein |
CTD |
PMID:25449126 |
|
NCBI chr 4:131,965,676...132,177,790
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of MKI67 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 1:199,926,150...199,952,847
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
Chlorpromazine inhibits the reaction [FSL-1 lipoprotein, synthetic results in increased expression of MMP9 mRNA]; Chlorpromazine inhibits the reaction [FSL-1 lipoprotein, synthetic results in increased secretion of MMP9 protein] |
CTD |
PMID:25200491 |
|
NCBI chr 3:174,103,474...174,111,434
|
|
G |
Msc |
musculin |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of MSC mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 5:4,547,335...4,553,206
|
|
G |
Msh2 |
mutS homolog 2 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of MSH2 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 6:12,567,368...12,626,534
|
|
G |
Mst1 |
macrophage stimulating 1 |
increases phosphorylation |
ISO |
Chlorpromazine results in increased phosphorylation of MST1 protein |
CTD |
PMID:30703373 |
|
NCBI chr 8:117,646,485...117,652,016
|
|
G |
Mt1 |
metallothionein 1 |
increases expression |
EXP |
Chlorpromazine results in increased expression of MT1A mRNA |
CTD |
PMID:8128501 |
|
NCBI chr19:10,831,959...10,832,975
|
|
G |
Mybl2 |
MYB proto-oncogene like 2 |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of MYBL2 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 3:172,124,765...172,153,221
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of MYC mRNA |
CTD |
PMID:30703373 |
|
NCBI chr 7:95,483,105...95,488,031
|
|
G |
Nampt |
nicotinamide phosphoribosyltransferase |
increases expression |
EXP |
Chlorpromazine results in increased expression of NAMPT mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 6:55,152,756...55,189,547
|
|
G |
Nanog |
Nanog homeobox |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of NANOG mRNA |
CTD |
PMID:30703373 |
|
NCBI chr 4:155,943,737...155,951,116
|
|
G |
Ndufs3 |
NADH:ubiquinone oxidoreductase core subunit S3 |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of NDUFS3 protein |
CTD |
PMID:19441803 |
|
NCBI chr 3:76,876,646...76,883,824
|
|
G |
Nectin2 |
nectin cell adhesion molecule 2 |
multiple interactions |
ISO |
Chlorpromazine inhibits the reaction [Cadmium Chloride results in decreased expression of and affects the localization of NECTIN2 protein] |
CTD |
PMID:25046863 |
|
NCBI chr 1:79,372,123...79,407,379
|
|
G |
Nedd9 |
neural precursor cell expressed, developmentally down-regulated 9 |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of NEDD9 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr17:23,289,793...23,468,026
|
|
G |
Nefh |
neurofilament heavy chain |
affects expression |
EXP |
Chlorpromazine affects the expression of NEFH mRNA |
CTD |
PMID:31324950 |
|
NCBI chr14:84,044,428...84,054,413
|
|
G |
Nfatc1 |
nuclear factor of activated T-cells 1 |
multiple interactions |
ISO |
Chlorpromazine inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 mRNA] |
CTD |
PMID:21869564 |
|
NCBI chr18:76,321,386...76,430,997
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
decreases expression affects activity |
EXP |
Chlorpromazine results in decreased expression of NFE2L2 mRNA Chlorpromazine affects the activity of NFE2L2 protein |
CTD |
PMID:25596134 |
|
NCBI chr 3:81,001,529...81,031,165
|
|
G |
Ninj1 |
ninjurin 1 |
increases expression |
EXP |
Chlorpromazine results in increased expression of NINJ1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr17:15,659,208...15,668,115
|
|
G |
Nppb |
natriuretic peptide B |
increases expression |
EXP |
Chlorpromazine results in increased expression of NPPB protein |
CTD |
PMID:36751017 |
|
NCBI chr 5:163,699,955...163,701,314
|
|
G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
increases expression |
ISO |
Chlorpromazine results in increased expression of NR0B2 mRNA |
CTD |
PMID:17175557 |
|
NCBI chr 5:145,779,294...145,782,609
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of NR1H4 mRNA |
CTD |
PMID:27765674 PMID:28391356 |
|
NCBI chr 7:25,733,471...25,829,440
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases expression multiple interactions |
ISO |
Chlorpromazine analog results in increased expression of NR1I2 mRNA [Chlorpromazine results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA |
CTD |
PMID:15924885 PMID:17041008 |
|
NCBI chr11:75,965,717...76,006,733
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
increases activity increases expression multiple interactions |
ISO |
Chlorpromazine results in increased activity of NR1I3 protein Chlorpromazine results in increased expression of NR1I3 mRNA [Chlorpromazine co-treated with Cholic Acids] affects the expression of NR1I3 mRNA; [Chlorpromazine results in increased activity of NR1I3 protein alternative form] which results in increased expression of CYP2B6 mRNA; Chlorpromazine inhibits the reaction [Androstenols inhibits the reaction [NR1I3 protein results in increased expression of CYP2B6 mRNA]] NR1I3 protein affects the reaction [Chlorpromazine results in increased expression of CYP2B10 mRNA]; NR1I3 protein affects the reaction [Chlorpromazine results in increased expression of CYP3A11 mRNA] |
CTD |
PMID:10037683 PMID:12049174 PMID:12948398 PMID:17041008 PMID:22310298 PMID:27344345 More...
|
|
NCBI chr13:86,165,327...86,170,362
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
multiple interactions |
ISO |
Chlorpromazine inhibits the reaction [Corticosterone results in increased activity of NR3C1 protein] |
CTD |
PMID:16581232 |
|
NCBI chr18:31,522,783...31,644,508
|
|
G |
Nupr1 |
nuclear protein 1, transcriptional regulator |
increases expression |
ISO |
Chlorpromazine results in increased expression of NUPR1 mRNA |
CTD |
PMID:15342952 PMID:17175557 |
|
NCBI chr 1:190,643,866...190,645,901
|
|
G |
Orc1 |
origin recognition complex, subunit 1 |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of ORC1 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 5:128,552,975...128,581,943
|
|
G |
Orm1 |
orosomucoid 1 |
affects binding multiple interactions |
ISO |
Chlorpromazine binds to ORM1 protein alternative form Chlorpromazine inhibits the reaction [Warfarin binds to ORM1 protein alternative form] |
CTD |
PMID:8946472 |
|
NCBI chr 5:81,788,509...81,791,661
|
|
G |
Pdia2 |
protein disulfide isomerase family A, member 2 |
increases expression |
ISO |
Chlorpromazine analog results in increased expression of PDIA2 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr10:15,215,824...15,218,937
|
|
G |
Pdia5 |
protein disulfide isomerase family A, member 5 |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of PDIA5 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr11:65,272,152...65,359,087
|
|
G |
Pdk1 |
pyruvate dehydrogenase kinase 1 |
increases expression |
EXP |
Chlorpromazine results in increased expression of PDK1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 3:77,113,464...77,144,145
|
|
G |
Pdk4 |
pyruvate dehydrogenase kinase 4 |
increases expression |
EXP |
Chlorpromazine results in increased expression of PDK4 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 4:34,558,327...34,568,329
|
|
G |
Phyh |
phytanoyl-CoA 2-hydroxylase |
increases expression |
ISO |
Chlorpromazine results in increased expression of PHYH mRNA |
CTD |
PMID:15342952 |
|
NCBI chr17:73,329,461...73,346,359
|
|
G |
Pias1 |
protein inhibitor of activated STAT, 1 |
increases expression |
ISO |
Chlorpromazine results in increased expression of PIAS1 mRNA |
CTD |
PMID:21683644 |
|
NCBI chr 8:63,338,150...63,451,670
|
|
G |
Pim1 |
Pim-1 proto-oncogene, serine/threonine kinase |
increases expression |
ISO |
Chlorpromazine analog results in increased expression of PIM1 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr20:7,556,496...7,560,747
|
|
G |
Pir |
pirin |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of PIR mRNA |
CTD |
PMID:25596134 |
|
NCBI chr X:33,740,428...33,851,049
|
|
G |
Plin2 |
perilipin 2 |
increases expression |
EXP |
Chlorpromazine results in increased expression of PLIN2 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 5:106,202,634...106,258,748
|
|
G |
Pmepa1 |
prostate transmembrane protein, androgen induced 1 |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of PMEPA1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 3:162,011,884...162,060,343
|
|
G |
Pola1 |
DNA polymerase alpha 1, catalytic subunit |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of POLA1 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr X:62,028,475...62,342,455
|
|
G |
Pold4 |
DNA polymerase delta 4, accessory subunit |
increases expression |
ISO |
Chlorpromazine analog results in increased expression of POLD4 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 1:201,526,591...201,528,406
|
|
G |
Pou5f1 |
POU class 5 homeobox 1 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of POU5F1 mRNA |
CTD |
PMID:30703373 |
|
NCBI chr20:3,227,836...3,232,598
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
affects activity |
EXP |
Chlorpromazine affects the activity of PPARG protein |
CTD |
PMID:25596134 |
|
NCBI chr 4:150,095,743...150,221,104
|
|
G |
Ppp1r15a |
protein phosphatase 1, regulatory subunit 15A |
increases expression |
EXP |
Chlorpromazine results in increased expression of PPP1R15A mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 1:105,136,521...105,139,596
|
|
G |
Prkaa1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
decreases phosphorylation |
EXP |
Chlorpromazine results in decreased phosphorylation of PRKAA1 protein |
CTD |
PMID:17512020 |
|
NCBI chr 2:55,967,766...56,003,450
|
|
G |
Prl |
prolactin |
increases expression |
ISO |
Chlorpromazine results in increased expression of PRL protein |
CTD |
PMID:718334 PMID:996201 |
|
NCBI chr17:38,287,355...38,298,234
|
|
G |
Rara |
retinoic acid receptor, alpha |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of RARA mRNA |
CTD |
PMID:18246545 |
|
NCBI chr10:83,883,490...83,928,932
|
|
G |
Rnd1 |
Rho family GTPase 1 |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of RND1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 7:129,821,311...129,828,385
|
|
G |
Rnd3 |
Rho family GTPase 3 |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of RND3 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 3:55,981,142...55,998,494
|
|
G |
Rnf121 |
ring finger protein 121 |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of RNF121 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 1:156,377,368...156,439,936
|
|
G |
Runx1 |
RUNX family transcription factor 1 |
increases expression |
EXP |
Chlorpromazine results in increased expression of RUNX1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr11:45,325,778...45,560,300
|
|
G |
Rxrg |
retinoid X receptor gamma |
affects response to substance |
ISO |
RXRG protein affects the susceptibility to Chlorpromazine |
CTD |
PMID:10336693 |
|
NCBI chr13:82,276,330...82,318,097
|
|
G |
Sat1 |
spermidine/spermine N1-acetyl transferase 1 |
increases expression |
EXP |
Chlorpromazine results in increased expression of SAT1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr X:44,008,089...44,011,376
|
|
G |
Sc5d |
sterol-C5-desaturase |
increases expression |
ISO |
Chlorpromazine results in increased expression of SC5D mRNA |
CTD |
PMID:17052361 |
|
NCBI chr 8:42,629,649...42,641,257
|
|
G |
Serpina3n |
serpin family A member 3N |
increases expression |
ISO |
Chlorpromazine results in increased expression of SERPINA3 mRNA |
CTD |
PMID:15342952 PMID:17175557 |
|
NCBI chr 6:123,323,623...123,331,181
|
|
G |
Serpinh1 |
serpin family H member 1 |
increases expression |
ISO |
Chlorpromazine results in increased expression of SERPINH1 mRNA |
CTD |
PMID:35708773 |
|
NCBI chr 1:153,643,500...153,650,853
|
|
G |
Sesn1 |
sestrin 1 |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of SESN1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr20:46,876,918...46,970,010
|
|
G |
Sik1 |
salt-inducible kinase 1 |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of SIK1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr20:9,947,104...9,958,729
|
|
G |
Slc10a1 |
solute carrier family 10 member 1 |
decreases expression increases expression |
EXP ISO |
Chlorpromazine results in decreased expression of SLC10A1 mRNA Chlorpromazine results in increased expression of SLC10A1 mRNA |
CTD |
PMID:27765674 PMID:28391356 PMID:35708773 |
|
NCBI chr 6:100,613,045...100,626,670
|
|
G |
Slc12a8 |
solute carrier family 12, member 8 |
increases expression |
EXP |
Chlorpromazine results in increased expression of SLC12A8 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr11:67,116,876...67,266,548
|
|
G |
Slc19a1 |
solute carrier family 19 member 1 |
multiple interactions decreases activity |
EXP |
Chlorpromazine inhibits the reaction [SLC19A1 protein results in increased uptake of Methotrexate] Chlorpromazine results in decreased activity of SLC19A1 protein |
CTD |
PMID:17482559 |
|
NCBI chr20:11,584,410...11,602,429
|
|
G |
Slc1a5 |
solute carrier family 1 member 5 |
increases expression |
EXP |
Chlorpromazine results in increased expression of SLC1A5 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 1:77,456,849...77,470,952
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Chlorpromazine inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:50,668,817...50,711,019
|
|
G |
Slc22a7 |
solute carrier family 22 member 7 |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of SLC22A7 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr 9:14,547,073...14,554,354
|
|
G |
Slc2a3 |
solute carrier family 2 member 3 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of SLC2A3 mRNA |
CTD |
PMID:15342952 |
|
NCBI chr 4:157,632,887...157,698,034
|
|
G |
Slc31a1 |
solute carrier family 31 member 1 |
multiple interactions |
ISO |
Chlorpromazine inhibits the reaction [Copper affects the localization of SLC31A1 protein] |
CTD |
PMID:12501239 |
|
NCBI chr 5:75,814,744...75,844,241
|
|
G |
Slc3a2 |
solute carrier family 3 member 2 |
increases expression |
EXP |
Chlorpromazine results in increased expression of SLC3A2 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 1:215,033,601...215,048,064
|
|
G |
Slc51b |
SLC51 subunit beta |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of SLC51B mRNA |
CTD |
PMID:27344345 |
|
NCBI chr 8:65,931,891...65,939,953
|
|
G |
Slc6a6 |
solute carrier family 6 member 6 |
increases expression |
EXP |
Chlorpromazine results in increased expression of SLC6A6 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 4:124,195,186...124,268,880
|
|
G |
Slco2b1 |
solute carrier organic anion transporter family, member 2b1 |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of SLCO2B1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 1:153,959,288...154,007,294
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
EXP |
Chlorpromazine inhibits the reaction [Copper inhibits the reaction [Trientine results in decreased activity of SOD1 protein]] |
CTD |
PMID:22362149 |
|
NCBI chr11:42,942,742...42,948,399
|
|
G |
Sox2 |
SRY-box transcription factor 2 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of SOX2 mRNA |
CTD |
PMID:30703373 |
|
NCBI chr 2:117,536,929...117,539,340
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of SPP1 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr14:5,613,569...5,620,695
|
|
G |
Spsb1 |
splA/ryanodine receptor domain and SOCS box containing 1 |
increases expression |
EXP |
Chlorpromazine results in increased expression of SPSB1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 5:160,358,292...160,418,541
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
multiple interactions |
EXP |
Chlorpromazine inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased phosphorylation of SRC protein] |
CTD |
PMID:29702141 |
|
NCBI chr 3:166,511,616...166,559,463
|
|
G |
Srebf2 |
sterol regulatory element binding transcription factor 2 |
multiple interactions |
ISO |
Chlorpromazine results in increased cleavage of and results in increased activity of SREBF2 protein |
CTD |
PMID:17052361 |
|
NCBI chr 7:115,542,774...115,600,945
|
|
G |
Strbp |
spermatid perinuclear RNA binding protein |
increases expression |
EXP |
Chlorpromazine results in increased expression of STRBP mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 3:21,328,310...21,467,753
|
|
G |
Sts |
steroid sulfatase |
multiple interactions |
ISO |
Chlorpromazine inhibits the reaction [Tretinoin results in increased activity of STS protein] |
CTD |
PMID:16178010 |
|
NCBI chr X:46,102,524...46,110,868
|
|
G |
Tagln |
transgelin |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of TAGLN mRNA |
CTD |
PMID:17175557 |
|
NCBI chr 8:55,121,647...55,127,121
|
|
G |
Tf |
transferrin |
affects localization |
ISO |
Chlorpromazine affects the localization of TF protein |
CTD |
PMID:12501239 |
|
NCBI chr 8:103,789,780...103,816,487
|
|
G |
Tfdp1 |
transcription factor Dp-1 |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of TFDP1 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr16:82,864,220...82,903,166
|
|
G |
Tiparp |
TCDD-inducible poly(ADP-ribose) polymerase |
increases expression |
EXP |
Chlorpromazine results in increased expression of TIPARP mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 2:149,753,682...149,780,327
|
|
G |
Tirap |
TIR domain containing adaptor protein |
multiple interactions |
ISO |
TIRAP gene mutant form inhibits the reaction [[Chlorpromazine co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of TNF protein]; TIRAP gene mutant form inhibits the reaction [[Chlorpromazine co-treated with lipoteichoic acid] results in increased expression of TNF protein]; TIRAP gene mutant form inhibits the reaction [[Chlorpromazine co-treated with lipoteichoic acid] results in increased phosphorylation of MAPK8 protein]; TIRAP gene mutant form inhibits the reaction [Chlorpromazine promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of MAPK8 protein]]; TIRAP protein results in increased susceptibility to [Chlorpromazine co-treated with lipopolysaccharide, Escherichia coli O111 B4]; TIRAP protein results in increased susceptibility to [Chlorpromazine co-treated with lipoteichoic acid] |
CTD |
PMID:23238562 |
|
NCBI chr 8:41,789,557...41,805,903
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression increases response to substance multiple interactions |
ISO |
Chlorpromazine analog results in decreased expression of TNF protein; Chlorpromazine results in decreased expression of TNF mRNA TNF protein results in increased susceptibility to Chlorpromazine [Chlorpromazine co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of TNF protein; [Chlorpromazine co-treated with lipoteichoic acid] results in increased expression of TNF protein; Chlorpromazine inhibits the reaction [[hydroquinone results in increased expression of TNF protein] which results in increased susceptibility to Methacholine Chloride]; Chlorpromazine inhibits the reaction [hydroquinone results in increased expression of TNF protein]; pyrazolanthrone inhibits the reaction [TNF protein results in increased susceptibility to Chlorpromazine]; TIRAP gene mutant form inhibits the reaction [[Chlorpromazine co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of TNF protein]; TIRAP gene mutant form inhibits the reaction [[Chlorpromazine co-treated with lipoteichoic acid] results in increased expression of TNF protein] [IL6 protein co-treated with IL1A protein co-treated with TNF protein co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased susceptibility to Chlorpromazine; Chlorpromazine results in decreased expression of and results in decreased activity of TNF protein |
CTD |
PMID:8550079 PMID:15052360 PMID:19362101 PMID:20371967 PMID:22414385 PMID:23238562 More...
|
|
NCBI chr20:3,626,685...3,629,303
|
|
G |
Tnfaip8 |
TNF alpha induced protein 8 |
increases expression |
EXP |
Chlorpromazine results in increased expression of TNFAIP8 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr18:45,370,334...45,486,036
|
|
G |
Tnfrsf14 |
TNF receptor superfamily member 14 |
increases expression |
ISO |
Chlorpromazine analog results in increased expression of TNFRSF14 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 5:170,768,413...170,776,749
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
decreases activity multiple interactions |
ISO |
Chlorpromazine results in decreased activity of TNFSF11; Chlorpromazine results in decreased activity of TNFSF11 protein Chlorpromazine inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 mRNA]; Chlorpromazine inhibits the reaction [TNFSF11 protein results in increased expression of CALCR mRNA]; Chlorpromazine inhibits the reaction [TNFSF11 protein results in increased expression of CAR2 mRNA]; Chlorpromazine inhibits the reaction [TNFSF11 protein results in increased expression of CTSK mRNA]; Chlorpromazine inhibits the reaction [TNFSF11 protein results in increased expression of DCSTAMP mRNA]; Chlorpromazine inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 mRNA] |
CTD |
PMID:21869564 |
|
NCBI chr15:60,083,008...60,114,479
|
|
G |
Tp53 |
tumor protein p53 |
affects activity |
EXP |
Chlorpromazine affects the activity of TP53 protein |
CTD |
PMID:25596134 |
|
NCBI chr10:54,798,871...54,810,300
|
|
G |
Trafd1 |
TRAF type zinc finger domain containing 1 |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of TRAFD1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr12:40,826,251...40,840,169
|
|
G |
Tuba1a |
tubulin, alpha 1A |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of TUBA1A mRNA |
CTD |
PMID:27015953 |
|
NCBI chr 7:131,992,151...131,996,850
|
|
G |
Txn1 |
thioredoxin 1 |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of TXN1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 5:77,507,455...77,519,685
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of TXNRD1 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr 7:22,717,620...22,802,553
|
|
G |
Tyr |
tyrosinase |
increases expression |
ISO |
Chlorpromazine results in increased expression of TYR protein |
CTD |
PMID:25449126 |
|
NCBI chr 1:150,527,687...150,622,857
|
|
G |
Ung |
uracil-DNA glycosylase |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of UNG mRNA |
CTD |
PMID:15924885 |
|
NCBI chr12:48,145,838...48,154,789
|
|
G |
Unkl |
unk like zinc finger |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of UNKL mRNA |
CTD |
PMID:25596134 |
|
NCBI chr10:14,206,125...14,252,226
|
|
G |
Vegfa |
vascular endothelial growth factor A |
increases expression |
ISO |
Chlorpromazine analog results in increased expression of VEGFA mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 9:22,452,854...22,468,194
|
|
G |
Vegfb |
vascular endothelial growth factor B |
increases expression |
EXP |
Chlorpromazine results in increased expression of VEGFB mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 1:213,601,570...213,607,254
|
|
G |
Wars1 |
tryptophanyl-tRNA synthetase 1 |
increases expression |
EXP |
Chlorpromazine results in increased expression of WARS1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 6:127,776,088...127,807,273
|
|
G |
Wipi1 |
WD repeat domain, phosphoinositide interacting 1 |
increases expression |
ISO |
Chlorpromazine results in increased expression of WIPI1 mRNA |
CTD |
PMID:15342952 PMID:17175557 |
|
NCBI chr10:95,042,451...95,079,679
|
|
G |
Xbp1 |
X-box binding protein 1 |
affects activity decreases expression |
EXP |
Chlorpromazine affects the activity of XBP1 protein Chlorpromazine results in decreased expression of XBP1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr14:84,604,623...84,609,707
|
|
G |
Xpc |
XPC complex subunit, DNA damage recognition and repair factor |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of XPC mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 4:123,993,670...124,020,922
|
|
G |
Xrcc4 |
X-ray repair cross complementing 4 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of XRCC4 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 2:20,948,464...21,197,705
|
|
G |
Yap1 |
Yes1 associated transcriptional regulator |
multiple interactions |
ISO |
Chlorpromazine results in decreased expression of and results in increased phosphorylation of and affects the localization of YAP1 protein |
CTD |
PMID:30703373 |
|
NCBI chr 8:5,095,705...5,166,808
|
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
clidinium inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:50,668,817...50,711,019
|
|
|
G |
Abhd2 |
abhydrolase domain containing 2, acylglycerol lipase |
decreases expression |
ISO |
Clomiphene results in decreased expression of ABHD2 mRNA |
CTD |
PMID:26865669 |
|
NCBI chr 1:142,626,748...142,707,892
|
|
G |
Ar |
androgen receptor |
affects binding multiple interactions |
EXP ISO |
Clomiphene binds to AR protein Clomiphene binds to and results in decreased activity of AR protein; Clomiphene inhibits the reaction [[6-fluorotestosterone co-treated with Norgestrel] binds to and results in increased activity of AR protein] |
CTD |
PMID:14565775 PMID:25752796 PMID:33049310 |
|
NCBI chr X:63,104,771...63,273,934
|
|
G |
Car12 |
carbonic anhydrase 12 |
decreases expression |
ISO |
Clomiphene results in decreased expression of CA12 mRNA |
CTD |
PMID:26865669 |
|
NCBI chr 8:67,274,739...67,330,428
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
ISO |
Clomiphene results in decreased expression of CCND1 mRNA |
CTD |
PMID:26865669 |
|
NCBI chr 1:209,518,288...209,527,986
|
|
G |
Ccng2 |
cyclin G2 |
increases expression |
ISO |
Clomiphene results in increased expression of CCNG2 mRNA |
CTD |
PMID:26865669 |
|
NCBI chr14:15,088,694...15,097,190
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
decreases expression |
ISO |
Clomiphene results in decreased expression of CXCL12 mRNA |
CTD |
PMID:26865669 |
|
NCBI chr 4:152,060,781...152,073,628
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases activity |
ISO |
Clomiphene results in decreased activity of CYP1A1 protein |
CTD |
PMID:33814510 |
|
NCBI chr 8:66,991,940...66,998,014
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases activity |
ISO |
Clomiphene results in decreased activity of CYP1B1 protein |
CTD |
PMID:33814510 |
|
NCBI chr 6:21,093,927...21,103,091
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
[Clomiphene results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA |
CTD |
PMID:25455453 |
|
NCBI chr12:14,321,771...14,343,886
|
|
G |
Dkk1 |
dickkopf WNT signaling pathway inhibitor 1 |
decreases expression |
ISO |
Clomiphene results in decreased expression of DKK1 protein |
CTD |
PMID:21851939 |
|
NCBI chr 1:237,794,969...237,798,650
|
|
G |
Efna1 |
ephrin A1 |
increases expression |
ISO |
Clomiphene results in increased expression of EFNA1 mRNA |
CTD |
PMID:26865669 |
|
NCBI chr 2:174,681,676...174,689,061
|
|
G |
Egr3 |
early growth response 3 |
decreases expression |
ISO |
Clomiphene results in decreased expression of EGR3 mRNA |
CTD |
PMID:26865669 |
|
NCBI chr15:51,560,482...51,565,778
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions affects binding |
ISO |
Clomiphene binds to and results in decreased activity of ESR1 protein; Clomiphene inhibits the reaction [16 alpha-iodoestradiol binds to ESR1 protein]; Clomiphene promotes the reaction [ESR1 protein alternative form binds to ESR1 protein alternative form] Clomiphene binds to ESR1 protein |
CTD |
PMID:9048584 PMID:15521089 PMID:19233257 PMID:25012808 PMID:25752796 PMID:26865669 PMID:33049310 More...
|
|
NCBI chr 1:43,511,685...43,904,454
|
|
G |
Esr2 |
estrogen receptor 2 |
increases activity affects binding multiple interactions |
EXP ISO |
Clomiphene results in increased activity of ESR2 protein Clomiphene binds to Esr2 protein Clomiphene binds to and results in decreased activity of ESR2 protein Clomiphene binds to ESR2 protein Clomiphene inhibits the reaction [16 alpha-iodoestradiol binds to ESR2 protein] |
CTD RGD |
PMID:9048584 PMID:12224631 PMID:19211805 PMID:25752796 PMID:9048584 |
RGD:8694130 |
NCBI chr 6:100,589,553...100,645,240
|
|
G |
F3 |
coagulation factor III, tissue factor |
increases expression |
ISO |
Clomiphene results in increased expression of F3 protein |
CTD |
PMID:25569083 |
|
NCBI chr 2:212,511,675...212,523,375
|
|
G |
F5 |
coagulation factor V |
affects response to substance |
ISO |
F5 gene polymorphism affects the susceptibility to Clomiphene |
CTD |
PMID:19371211 |
|
NCBI chr13:79,046,657...79,116,247
|
|
G |
Foxc1 |
forkhead box C1 |
decreases expression |
ISO |
Clomiphene results in decreased expression of FOXC1 mRNA |
CTD |
PMID:26865669 |
|
NCBI chr17:32,631,379...32,635,361
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
multiple interactions increases expression |
ISO |
Clomiphene promotes the reaction [Alcohols results in increased expression of FSHB protein] Clomiphene results in increased expression of FSHB protein |
CTD |
PMID:1915937 PMID:8590623 |
|
NCBI chr 3:114,003,262...114,007,072
|
|
G |
Gnrh1 |
gonadotropin releasing hormone 1 |
multiple interactions |
ISO |
Clomiphene inhibits the reaction [Estradiol promotes the reaction [GNRH1 protein results in increased secretion of PRL protein]] |
CTD |
PMID:17054466 |
|
NCBI chr15:41,972,482...41,976,690
|
|
G |
Hoxa10 |
homeobox A10 |
decreases expression |
ISO |
Clomiphene results in decreased expression of HOXA10 mRNA; Clomiphene results in decreased expression of HOXA10 protein |
CTD |
PMID:26603317 |
|
NCBI chr 4:81,331,591...81,340,878
|
|
G |
Id3 |
inhibitor of DNA binding 3 |
increases expression |
ISO |
Clomiphene results in increased expression of ID3 mRNA |
CTD |
PMID:26865669 |
|
NCBI chr 5:153,656,253...153,657,860
|
|
G |
Itgb3 |
integrin subunit beta 3 |
decreases expression |
ISO |
Clomiphene results in decreased expression of ITGB3 protein Clomiphene results in decreased expression of ITGB3 mRNA; Clomiphene results in decreased expression of ITGB3 protein |
CTD |
PMID:15749485 PMID:26603317 |
|
NCBI chr10:90,009,927...90,067,787
|
|
G |
Iyd |
iodotyrosine deiodinase |
multiple interactions |
ISO |
Clomiphene inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine] |
CTD |
PMID:33352258 |
|
NCBI chr 1:42,410,099...42,425,414
|
|
G |
Jak2 |
Janus kinase 2 |
decreases expression |
ISO |
Clomiphene results in decreased expression of JAK2 mRNA |
CTD |
PMID:26865669 |
|
NCBI chr 1:236,408,905...236,468,769
|
|
G |
Kynu |
kynureninase |
increases expression |
ISO |
Clomiphene results in increased expression of KYNU mRNA |
CTD |
PMID:26865669 |
|
NCBI chr 3:48,188,286...48,338,996
|
|
G |
Lhb |
luteinizing hormone subunit beta |
increases secretion multiple interactions |
ISO |
Clomiphene results in increased secretion of LHB protein Clomiphene promotes the reaction [Alcohols results in increased expression of LHB protein]; PRL protein inhibits the reaction [Clomiphene results in increased secretion of LHB protein] |
CTD |
PMID:3891423 PMID:8590623 |
|
NCBI chr 1:105,037,457...105,038,446
|
|
G |
Lif |
LIF, interleukin 6 family cytokine |
increases expression decreases expression |
ISO |
Clomiphene results in increased expression of LIF mRNA Clomiphene results in decreased expression of LIF mRNA; Clomiphene results in decreased expression of LIF protein |
CTD |
PMID:21851939 PMID:26603317 |
|
NCBI chr14:83,354,602...83,364,053
|
|
G |
Myb |
MYB proto-oncogene, transcription factor |
decreases expression |
ISO |
Clomiphene results in decreased expression of MYB mRNA |
CTD |
PMID:26865669 |
|
NCBI chr 1:15,939,771...15,973,367
|
|
G |
Mybl1 |
MYB proto-oncogene like 1 |
decreases expression |
ISO |
Clomiphene results in decreased expression of MYBL1 mRNA |
CTD |
PMID:26865669 |
|
NCBI chr 5:9,582,905...9,618,179
|
|
G |
Nmrk1 |
nicotinamide riboside kinase 1 |
decreases expression |
ISO |
Clomiphene results in decreased expression of NMRK1 mRNA |
CTD |
PMID:26865669 |
|
NCBI chr 1:225,475,975...225,503,414
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity multiple interactions |
ISO |
Clomiphene results in increased activity of NR1I2 protein Clomiphene binds to and results in increased activity of NR1I2 protein [Clomiphene results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; Clomiphene binds to and results in increased activity of NR1I2 protein |
CTD |
PMID:25455453 PMID:33049310 |
|
NCBI chr11:75,965,717...76,006,733
|
|
G |
Olfm1 |
olfactomedin 1 |
decreases expression |
ISO |
Clomiphene results in decreased expression of OLFM1 mRNA |
CTD |
PMID:26865669 |
|
NCBI chr 3:11,520,522...11,558,240
|
|
G |
Pdzk1 |
PDZ domain containing 1 |
decreases expression |
ISO |
Clomiphene results in decreased expression of PDZK1 mRNA |
CTD |
PMID:26865669 |
|
NCBI chr 2:184,376,161...184,407,514
|
|
G |
Pgr |
progesterone receptor |
increases expression multiple interactions |
ISO |
Clomiphene results in increased expression of PGR protein Clomiphene binds to and results in decreased activity of PGR protein |
CTD |
PMID:15749485 PMID:25752796 |
|
NCBI chr 8:14,354,398...14,413,271
|
|
G |
Pik3r3 |
phosphoinositide-3-kinase regulatory subunit 3 |
increases expression |
ISO |
Clomiphene results in increased expression of PIK3R3 mRNA |
CTD |
PMID:26865669 |
|
NCBI chr 5:134,936,790...135,009,303
|
|
G |
Prkce |
protein kinase C, epsilon |
affects localization |
ISO |
Clomiphene affects the localization of PRKCE protein |
CTD |
PMID:9714066 |
|
NCBI chr 6:13,718,050...14,204,931
|
|
G |
Prl |
prolactin |
multiple interactions |
ISO |
Clomiphene inhibits the reaction [Estradiol promotes the reaction [GNRH1 protein results in increased secretion of PRL protein]]; Clomiphene inhibits the reaction [Estradiol results in increased secretion of PRL protein]; PRL protein inhibits the reaction [Clomiphene results in increased secretion of LHB protein] |
CTD |
PMID:3891423 PMID:17054466 |
|
NCBI chr17:38,287,355...38,298,234
|
|
G |
Prss23 |
serine protease 23 |
decreases expression |
ISO |
Clomiphene results in decreased expression of PRSS23 mRNA |
CTD |
PMID:26865669 |
|
NCBI chr 1:143,402,725...143,422,182
|
|
G |
Ptges |
prostaglandin E synthase |
decreases expression |
ISO |
Clomiphene results in decreased expression of PTGES mRNA |
CTD |
PMID:26865669 |
|
NCBI chr 3:14,177,892...14,189,236
|
|
G |
Rbbp8 |
RB binding protein 8, endonuclease |
decreases expression |
ISO |
Clomiphene results in decreased expression of RBBP8 mRNA |
CTD |
PMID:26865669 |
|
NCBI chr18:3,198,188...3,263,643
|
|
G |
Rcl1 |
RNA terminal phosphate cyclase-like 1 |
decreases expression |
ISO |
Clomiphene results in decreased expression of RCL1 mRNA |
CTD |
PMID:26865669 |
|
NCBI chr 1:236,238,078...236,282,597
|
|
G |
Ret |
ret proto-oncogene |
decreases expression |
ISO |
Clomiphene results in decreased expression of RET mRNA |
CTD |
PMID:26865669 |
|
NCBI chr 4:152,998,344...153,040,556
|
|
G |
Sgk1 |
serum/glucocorticoid regulated kinase 1 |
decreases expression |
ISO |
Clomiphene results in decreased expression of SGK1 mRNA |
CTD |
PMID:26865669 |
|
NCBI chr 1:24,799,391...24,916,886
|
|
G |
Sgk3 |
serum/glucocorticoid regulated kinase family, member 3 |
decreases expression |
ISO |
Clomiphene results in decreased expression of SGK3 mRNA |
CTD |
PMID:26865669 |
|
NCBI chr 5:14,128,628...14,255,099
|
|
G |
Shbg |
sex hormone binding globulin |
affects binding |
ISO |
Clomiphene binds to SHBG protein |
CTD |
PMID:25349334 |
|
NCBI chr10:54,332,939...54,350,409
|
|
G |
Siah2 |
siah E3 ubiquitin protein ligase 2 |
decreases expression |
ISO |
Clomiphene results in decreased expression of SIAH2 mRNA |
CTD |
PMID:26865669 |
|
NCBI chr 2:145,063,847...145,081,675
|
|
G |
Smox |
spermine oxidase |
decreases expression |
ISO |
Clomiphene results in decreased expression of SMOX mRNA |
CTD |
PMID:26865669 |
|
NCBI chr 3:118,731,814...118,767,242
|
|
G |
Ssbp2 |
single-stranded DNA binding protein 2 |
increases expression |
ISO |
Clomiphene results in increased expression of SSBP2 mRNA |
CTD |
PMID:26865669 |
|
NCBI chr 2:22,650,488...22,938,669
|
|
G |
Svil |
supervillin |
decreases expression |
ISO |
Clomiphene results in decreased expression of SVIL mRNA |
CTD |
PMID:26865669 |
|
NCBI chr17:52,648,502...52,844,114
|
|
G |
Tfap2a |
transcription factor AP-2 alpha |
increases expression |
ISO |
Clomiphene results in increased expression of TFAP2A mRNA |
CTD |
PMID:26865669 |
|
NCBI chr17:24,230,064...24,253,219
|
|
G |
Tfap2c |
transcription factor AP-2 gamma |
decreases expression |
ISO |
Clomiphene results in decreased expression of TFAP2C mRNA |
CTD |
PMID:26865669 |
|
NCBI chr 3:161,315,114...161,322,998
|
|
G |
Tfpi |
tissue factor pathway inhibitor |
increases expression |
ISO |
Clomiphene results in increased expression of TFPI mRNA |
CTD |
PMID:26865669 |
|
NCBI chr 3:89,939,862...89,989,253
|
|
G |
Thra |
thyroid hormone receptor alpha |
multiple interactions |
ISO |
Clomiphene binds to and results in increased activity of THRA protein |
CTD |
PMID:33049310 |
|
NCBI chr10:84,198,141...84,225,659
|
|
G |
Thrb |
thyroid hormone receptor beta |
multiple interactions |
ISO |
Clomiphene binds to and results in increased activity of THRB protein |
CTD |
PMID:33049310 |
|
NCBI chr15:10,115,954...10,465,231
|
|
|
G |
Casp3 |
caspase 3 |
increases expression |
EXP |
Cyproheptadine results in increased expression of CASP3 protein |
CTD |
PMID:33675893 |
|
NCBI chr16:52,395,539...52,413,794
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases activity |
ISO |
Cyproheptadine results in decreased activity of CYP1A1 protein |
CTD |
PMID:33814510 |
|
NCBI chr 8:66,991,940...66,998,014
|
|
G |
Gh1 |
growth hormone 1 |
increases expression |
ISO |
Cyproheptadine results in increased expression of GH1 protein |
CTD |
PMID:642945 |
|
NCBI chr10:91,727,883...91,729,860
|
|
G |
Hsf1 |
heat shock transcription factor 1 |
increases activity |
ISO |
Cyproheptadine results in increased activity of HSF1 protein |
CTD |
PMID:34170685 |
|
NCBI chr 7:110,076,710...110,103,665
|
|
G |
Htr2a |
5-hydroxytryptamine receptor 2A |
multiple interactions |
ISO |
Cyproheptadine binds to and results in decreased activity of HTR2A protein |
CTD |
PMID:17031071 |
|
NCBI chr15:56,360,647...56,428,703
|
|
G |
Htr7 |
5-hydroxytryptamine receptor 7 |
affects binding multiple interactions |
ISO |
Cyproheptadine binds to HTR7 protein Cyproheptadine inhibits the reaction [Risperidone binds to and results in decreased activity of HTR7 protein] |
CTD |
PMID:20827463 |
|
NCBI chr 1:243,049,064...243,173,636
|
|
G |
Il6 |
interleukin 6 |
decreases expression |
EXP |
Cyproheptadine results in decreased expression of IL6 protein |
CTD |
PMID:33675893 |
|
NCBI chr 4:5,889,999...5,894,575
|
|
G |
Kcnn2 |
potassium calcium-activated channel subfamily N member 2 |
decreases activity |
EXP |
Cyproheptadine results in decreased activity of KCNN2 protein |
CTD |
PMID:10915830 |
|
NCBI chr18:40,004,693...40,445,043
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
decreases expression |
EXP |
Cyproheptadine results in decreased expression of NFKB1 protein |
CTD |
PMID:33675893 |
|
NCBI chr 2:226,689,745...226,805,897
|
|
G |
Pomc |
proopiomelanocortin |
decreases secretion |
ISO |
Cyproheptadine results in decreased secretion of POMC protein |
CTD |
PMID:642945 |
|
NCBI chr 6:32,659,137...32,665,175
|
|
G |
Prl |
prolactin |
decreases secretion |
ISO |
Cyproheptadine results in decreased secretion of PRL protein |
CTD |
PMID:642945 |
|
NCBI chr17:38,287,355...38,298,234
|
|
G |
Sirt1 |
sirtuin 1 |
increases expression |
EXP |
Cyproheptadine results in increased expression of SIRT1 protein |
CTD |
PMID:33675893 |
|
NCBI chr20:25,305,953...25,328,000
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Cyproheptadine inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:50,668,817...50,711,019
|
|
G |
Slc22a5 |
solute carrier family 22 member 5 |
multiple interactions |
ISO |
Cyproheptadine affects the reaction [SLC22A5 gene mutant form affects the transport of and affects the abundance of Pyrilamine] |
CTD |
PMID:19821448 |
|
NCBI chr10:38,008,303...38,035,474
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
affects response to substance |
ISO |
ABCB1A protein affects the susceptibility to Dextropropoxyphene |
CTD |
PMID:15502009 |
|
NCBI chr 4:26,312,403...26,488,456
|
|
G |
Abcb1b |
ATP-binding cassette, sub-family B member 1B |
affects response to substance |
ISO |
ABCB1B protein affects the susceptibility to Dextropropoxyphene |
CTD |
PMID:15502009 |
|
NCBI chr 4:26,197,706...26,280,156
|
|
G |
Ces1d |
carboxylesterase 1D |
affects binding |
ISO |
Dextropropoxyphene binds to CES1 protein |
CTD |
PMID:10381793 |
|
NCBI chr19:30,046,494...30,085,039
|
|
G |
Ces2h |
carboxylesterase 2H |
affects binding |
ISO |
Dextropropoxyphene binds to CES2 protein |
CTD |
PMID:10381793 |
|
NCBI chr19:32,974,242...32,988,842
|
|
G |
Oprd1 |
opioid receptor, delta 1 |
multiple interactions affects binding |
EXP |
[Dextropropoxyphene binds to OPRD1 protein] which results in decreased uptake of Norepinephrine; [Dextropropoxyphene binds to OPRD1 protein] which results in decreased uptake of Serotonin |
CTD |
PMID:7562497 |
|
NCBI chr 5:149,590,244...149,624,999
|
|
G |
Oprk1 |
opioid receptor, kappa 1 |
multiple interactions affects binding |
EXP |
[Dextropropoxyphene binds to OPRK1 protein] which results in decreased uptake of Norepinephrine; [Dextropropoxyphene binds to OPRK1 protein] which results in decreased uptake of Serotonin |
CTD |
PMID:7562497 |
|
NCBI chr 5:18,657,866...18,675,671
|
|
G |
Oprm1 |
opioid receptor, mu 1 |
multiple interactions affects binding |
EXP |
[Dextropropoxyphene binds to OPRM1 protein] which results in decreased uptake of Norepinephrine; [Dextropropoxyphene binds to OPRM1 protein] which results in decreased uptake of Serotonin |
CTD |
PMID:7562497 |
|
NCBI chr 1:45,565,371...45,818,722
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Dextropropoxyphene inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:50,668,817...50,711,019
|
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Dicyclomine inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:50,668,817...50,711,019
|
|
|
G |
Tp53 |
tumor protein p53 |
affects activity |
ISO |
Diphenoxylate affects the activity of TP53 protein |
CTD |
PMID:35435491 |
|
NCBI chr10:54,798,871...54,810,300
|
|
|
G |
Hrh1 |
histamine receptor H 1 |
multiple interactions |
ISO |
diphenylpyraline binds to and results in increased activity of HRH1 protein; diphenylpyraline inhibits the reaction [Pyrilamine binds to HRH1 protein] |
CTD |
PMID:1912125 |
|
NCBI chr 4:149,120,511...149,204,267
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
ISO |
diphenylpyraline results in decreased activity of KCNH2 protein |
CTD |
PMID:28551711 |
|
NCBI chr 4:11,719,357...11,751,424
|
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
decreases activity |
ISO |
Doxylamine results in decreased activity of ABCB4 protein |
CTD |
PMID:28437613 |
|
NCBI chr 4:26,106,895...26,164,440
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
multiple interactions |
ISO |
Doxylamine binds to and results in increased activity of NR1I3 protein alternative form |
CTD |
PMID:20869355 |
|
NCBI chr13:86,165,327...86,170,362
|
|
|
G |
Ache |
acetylcholinesterase |
decreases activity |
EXP |
EPTC results in decreased activity of ACHE protein |
CTD |
PMID:14644616 |
|
NCBI chr12:25,042,882...25,050,608
|
|
G |
Aldh2 |
aldehyde dehydrogenase 2 family member |
decreases activity |
ISO |
EPTC metabolite results in decreased activity of ALDH2 protein |
CTD |
PMID:10513990 |
|
NCBI chr12:40,610,244...40,643,220
|
|
G |
Alox15 |
arachidonate 15-lipoxygenase |
affects response to substance |
ISO |
ALOX15 gene SNP affects the susceptibility to EPTC |
CTD |
PMID:22919386 |
|
NCBI chr10:55,559,060...55,567,535
|
|
G |
Chrna3 |
cholinergic receptor nicotinic alpha 3 subunit |
multiple interactions |
EXP |
EPTC results in decreased activity of [CHRNA3 protein binds to CHRNB2 protein]; EPTC results in decreased activity of [CHRNA3 protein binds to CHRNB4 protein] |
CTD |
PMID:14644616 |
|
NCBI chr 8:55,401,668...55,415,165
|
|
G |
Chrna4 |
cholinergic receptor nicotinic alpha 4 subunit |
multiple interactions |
EXP |
EPTC results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]; EPTC results in decreased activity of [CHRNA4 protein binds to CHRNB4 protein] |
CTD |
PMID:14644616 |
|
NCBI chr 3:168,136,246...168,157,839
|
|
G |
Chrnb2 |
cholinergic receptor nicotinic beta 2 subunit |
multiple interactions |
EXP |
EPTC results in decreased activity of [CHRNA3 protein binds to CHRNB2 protein]; EPTC results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein] |
CTD |
PMID:14644616 |
|
NCBI chr 2:175,181,402...175,189,619
|
|
G |
Chrnb4 |
cholinergic receptor nicotinic beta 4 subunit |
multiple interactions |
EXP |
EPTC results in decreased activity of [CHRNA3 protein binds to CHRNB4 protein]; EPTC results in decreased activity of [CHRNA4 protein binds to CHRNB4 protein] |
CTD |
PMID:14644616 |
|
NCBI chr 8:55,417,583...55,437,027
|
|
|
G |
Aldh1a2 |
aldehyde dehydrogenase 1 family, member A2 |
increases expression |
ISO |
fenpropidine results in increased expression of ALDH1A2 mRNA |
CTD |
PMID:34737147 |
|
NCBI chr 8:71,877,850...71,957,107
|
|
G |
Cyp26a1 |
cytochrome P450, family 26, subfamily a, polypeptide 1 |
increases expression |
ISO |
fenpropidine results in increased expression of CYP26A1 mRNA |
CTD |
PMID:34737147 |
|
NCBI chr 1:235,471,368...235,475,204
|
|
G |
Msmo1 |
methylsterol monooxygenase 1 |
increases expression |
ISO |
fenpropidine results in increased expression of MSMO1 mRNA |
CTD |
PMID:34737147 |
|
NCBI chr16:24,980,680...24,997,927
|
|
G |
Myh14 |
myosin heavy chain 14 |
decreases expression |
ISO |
fenpropidine results in decreased expression of MYH14 protein |
CTD |
PMID:34737147 |
|
NCBI chr 1:95,096,266...95,158,861
|
|
G |
Myh6 |
myosin heavy chain 6 |
decreases expression |
ISO |
fenpropidine results in decreased expression of MYH6 mRNA |
CTD |
PMID:34737147 |
|
NCBI chr15:32,388,102...32,413,663
|
|
G |
Nes |
nestin |
increases expression |
ISO |
fenpropidine results in increased expression of NES mRNA |
CTD |
PMID:34737147 |
|
NCBI chr 2:175,735,715...175,745,631
|
|
G |
Nkx2-5 |
NK2 homeobox 5 |
decreases expression |
ISO |
fenpropidine results in decreased expression of NKX2-5 mRNA |
CTD |
PMID:34737147 |
|
NCBI chr10:16,844,888...16,851,458
|
|
G |
Tfap2a |
transcription factor AP-2 alpha |
increases expression |
ISO |
fenpropidine results in increased expression of TFAP2A protein |
CTD |
PMID:34737147 |
|
NCBI chr17:24,230,064...24,253,219
|
|
G |
Tubb3 |
tubulin, beta 3 class III |
increases expression |
ISO |
fenpropidine results in increased expression of TUBB3 mRNA |
CTD |
PMID:34737147 |
|
NCBI chr19:68,365,687...68,374,741
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions |
ISO |
ferric nitrilotriacetate inhibits the reaction [Asbestos, Crocidolite results in increased expression of ABCB1 protein]; ferric nitrilotriacetate inhibits the reaction [Razoxane results in increased expression of ABCB1 protein] |
CTD |
PMID:18385176 |
|
NCBI chr 4:26,312,403...26,488,456
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
increases expression |
ISO |
ferric nitrilotriacetate results in increased expression of ABCC1 mRNA |
CTD |
PMID:18617210 |
|
NCBI chr10:1,022,041...1,162,431
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
increases expression |
ISO |
ferric nitrilotriacetate results in increased expression of ABCC2 mRNA |
CTD |
PMID:18617210 |
|
NCBI chr 1:252,613,875...252,672,459
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
increases expression |
ISO |
ferric nitrilotriacetate results in increased expression of ABCC4 mRNA |
CTD |
PMID:18617210 |
|
NCBI chr15:101,948,387...102,182,912
|
|
G |
Anxa2 |
annexin A2 |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of ANXA2 mRNA |
CTD |
PMID:10854235 |
|
NCBI chr 8:78,986,252...79,022,638
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of BAX mRNA |
CTD |
PMID:23208426 |
|
NCBI chr 1:105,076,472...105,081,906
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of BBC3 mRNA |
CTD |
PMID:23208426 |
|
NCBI chr 1:86,141,450...86,150,666
|
|
G |
Bik |
BCL2-interacting killer |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of BIK mRNA |
CTD |
PMID:23208426 |
|
NCBI chr 7:114,672,277...114,691,296
|
|
G |
Cald1 |
caldesmon 1 |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of CALD1 mRNA |
CTD |
PMID:10854235 |
|
NCBI chr 4:64,232,906...64,414,085
|
|
G |
Canx |
calnexin |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of CANX protein |
CTD |
PMID:16908007 |
|
NCBI chr10:35,124,941...35,157,954
|
|
G |
Casp12 |
caspase 12 |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of CASP12 mRNA |
CTD |
PMID:23208426 |
|
NCBI chr 8:10,927,188...10,954,442
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP |
[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased cleavage of and results in decreased expression of CASP3 protein; [ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased expression of CASP3 mRNA; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased cleavage of and results in decreased expression of CASP3 protein]; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased expression of CASP3 mRNA] |
CTD |
PMID:21907755 |
|
NCBI chr16:52,395,539...52,413,794
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
EXP |
[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased cleavage of and results in decreased expression of CASP8 protein; [ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased expression of CASP8 mRNA; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased cleavage of and results in decreased expression of CASP8 protein]; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased expression of CASP8 mRNA] |
CTD |
PMID:21907755 |
|
NCBI chr 9:67,747,109...67,806,699
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
EXP |
[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased cleavage of and results in decreased expression of CASP9 protein; [ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased expression of CASP9 mRNA; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased cleavage of and results in decreased expression of CASP9 protein]; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in decreased expression of CASP9 mRNA] |
CTD |
PMID:21907755 |
|
|
|
G |
Cat |
catalase |
multiple interactions decreases activity |
EXP |
[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in decreased activity of CAT protein; chrysin inhibits the reaction [ferric nitrilotriacetate results in decreased activity of CAT protein]; geraniol inhibits the reaction [ferric nitrilotriacetate results in decreased activity of CAT protein]; Hesperidin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in decreased activity of CAT protein]; Quercetin inhibits the reaction [ferric nitrilotriacetate results in decreased activity of CAT protein] |
CTD |
PMID:9667754 PMID:15198074 PMID:18684806 PMID:21907755 PMID:23194824 PMID:30098279 More...
|
|
NCBI chr 3:110,297,340...110,329,526
|
|
G |
Ccnd1 |
cyclin D1 |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of CCND1 mRNA; ferric nitrilotriacetate results in increased expression of CCND1 protein |
CTD |
PMID:18055543 |
|
NCBI chr 1:209,518,288...209,527,986
|
|
G |
Cd44 |
CD44 molecule |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of CD44 mRNA; ferric nitrilotriacetate results in increased expression of CD44 protein |
CTD |
PMID:18055543 |
|
NCBI chr 3:109,610,824...109,699,776
|
|
G |
Cd47 |
Cd47 molecule |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of CD47 mRNA |
CTD |
PMID:9119739 |
|
NCBI chr11:64,374,816...64,438,763
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of CDKN1A mRNA |
CTD |
PMID:23208426 |
|
NCBI chr20:7,150,820...7,161,373
|
|
G |
Chrm1 |
cholinergic receptor, muscarinic 1 |
decreases expression |
EXP |
ferric nitrilotriacetate results in decreased expression of CHRM1 mRNA |
CTD |
PMID:19490752 |
|
NCBI chr 1:205,567,226...205,583,001
|
|
G |
Chrm2 |
cholinergic receptor, muscarinic 2 |
decreases expression |
EXP |
ferric nitrilotriacetate results in decreased expression of CHRM2 mRNA |
CTD |
PMID:19490752 |
|
NCBI chr 4:65,981,136...66,116,128
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
increases expression multiple interactions |
EXP |
ferric nitrilotriacetate results in increased expression of COL1A1 protein ethylisopropylamiloride inhibits the reaction [ferric nitrilotriacetate results in increased expression of COL1A1 protein] |
CTD |
PMID:11159895 |
|
NCBI chr10:80,380,458...80,397,461
|
|
G |
Cygb |
cytoglobin |
multiple interactions |
EXP |
CYGB protein inhibits the reaction [[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TGFB1 mRNA]; CYGB protein inhibits the reaction [[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TIMP1 mRNA]; CYGB protein results in decreased susceptibility to [ferric nitrilotriacetate co-treated with Arachidonic Acid] |
CTD |
PMID:16581302 |
|
NCBI chr10:101,877,675...101,887,442
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
ISO |
[[Arachidonic Acid co-treated with ferric nitrilotriacetate co-treated with Ethanol] results in increased expression of CYP2E1 protein] which results in increased expression of KRT18 protein; [[Arachidonic Acid co-treated with ferric nitrilotriacetate co-treated with Ethanol] results in increased expression of CYP2E1 protein] which results in increased expression of KRT8 protein; [Arachidonic Acid co-treated with ferric nitrilotriacetate co-treated with Ethanol] results in increased expression of CYP2E1 protein; allyl sulfide inhibits the reaction [CYP2E1 protein results in increased susceptibility to [ferric nitrilotriacetate co-treated with Arachidonic Acid]]; CYP2E1 protein results in increased susceptibility to [ferric nitrilotriacetate co-treated with Arachidonic Acid]; Ditiocarb inhibits the reaction [CYP2E1 protein results in increased susceptibility to [ferric nitrilotriacetate co-treated with Arachidonic Acid]]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [CYP2E1 protein results in increased susceptibility to [ferric nitrilotriacetate co-treated with Arachidonic Acid]] |
CTD |
PMID:12086689 PMID:17034788 PMID:21352821 |
|
NCBI chr 1:205,269,967...205,280,365
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
ferric nitrilotriacetate results in increased expression of FOS mRNA |
CTD |
PMID:10381381 |
|
NCBI chr 6:110,852,188...110,855,054
|
|
G |
Fosl1 |
FOS like 1, AP-1 transcription factor subunit |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of FOSL1 mRNA; ferric nitrilotriacetate results in increased expression of FOSL1 protein |
CTD |
PMID:18055543 |
|
NCBI chr 1:212,183,885...212,192,391
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
decreases activity |
EXP |
ferric nitrilotriacetate results in decreased activity of G6PD protein |
CTD |
PMID:9667754 |
|
NCBI chr X:157,352,364...157,372,144
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression |
ISO |
ferric nitrilotriacetate results in increased expression of GCLC mRNA |
CTD |
PMID:18617210 |
|
NCBI chr 8:87,510,251...87,548,896
|
|
G |
Gsr |
glutathione-disulfide reductase |
decreases activity multiple interactions |
EXP |
ferric nitrilotriacetate results in decreased activity of GSR protein [Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in decreased activity of GSR protein; Hesperidin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in decreased activity of GSR protein]; Quercetin inhibits the reaction [ferric nitrilotriacetate results in decreased activity of GSR protein] |
CTD |
PMID:9667754 PMID:15198074 PMID:30098279 |
|
NCBI chr16:65,185,574...65,228,742
|
|
G |
Gtse1 |
G-2 and S-phase expressed 1 |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of GTSE1 mRNA |
CTD |
PMID:23208426 |
|
NCBI chr 7:118,829,793...118,846,662
|
|
G |
Havcr1 |
hepatitis A virus cellular receptor 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased secretion of HAVCR1 protein; [ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of HAVCR1 mRNA; [ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of HAVCR1 protein; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of HAVCR1 mRNA]; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of HAVCR1 protein]; Hesperidin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased secretion of HAVCR1 protein] |
CTD |
PMID:21907755 PMID:30098279 |
|
NCBI chr10:31,118,667...31,151,730
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions |
ISO |
ferric nitrilotriacetate inhibits the reaction [Asbestos, Crocidolite results in increased activity of HIF1A protein]; ferric nitrilotriacetate inhibits the reaction [Razoxane results in increased activity of HIF1A protein] |
CTD |
PMID:18385176 |
|
NCBI chr 6:98,357,788...98,405,068
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
EXP ISO |
ferric nitrilotriacetate results in increased expression of HMOX1 mRNA |
CTD |
PMID:18617210 PMID:19490752 |
|
NCBI chr19:13,452,365...13,479,823
|
|
G |
Hsp90aa1 |
heat shock protein 90 alpha family class A member 1 |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of HSP90AA1 mRNA |
CTD |
PMID:10854235 |
|
NCBI chr 6:135,523,604...135,529,687
|
|
G |
Il24 |
interleukin 24 |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of IL24 mRNA |
CTD |
PMID:23208426 |
|
NCBI chr13:44,905,362...44,910,760
|
|
G |
Il6 |
interleukin 6 |
increases expression multiple interactions |
ISO EXP |
ferric nitrilotriacetate results in increased expression of IL6 protein ferric nitrilotriacetate results in increased expression of IL6 mRNA [Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of IL6 protein; chrysin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of IL6 protein] |
CTD |
PMID:15781289 PMID:19490752 PMID:23194824 |
|
NCBI chr 4:5,889,999...5,894,575
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of JUN mRNA; ferric nitrilotriacetate results in increased expression of JUN protein |
CTD |
PMID:18055543 |
|
NCBI chr 5:115,009,900...115,012,993
|
|
G |
Krt18 |
keratin 18 |
multiple interactions |
ISO |
[[Arachidonic Acid co-treated with ferric nitrilotriacetate co-treated with Ethanol] results in increased expression of CYP2E1 protein] which results in increased expression of KRT18 protein |
CTD |
PMID:17034788 |
|
NCBI chr 7:135,036,168...135,039,844
|
|
G |
Krt8 |
keratin 8 |
multiple interactions |
ISO |
[[Arachidonic Acid co-treated with ferric nitrilotriacetate co-treated with Ethanol] results in increased expression of CYP2E1 protein] which results in increased expression of KRT8 protein |
CTD |
PMID:17034788 |
|
NCBI chr 7:135,002,886...135,010,339
|
|
G |
Mcm3 |
minichromosome maintenance complex component 3 |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of MCM3 mRNA |
CTD |
PMID:23208426 |
|
NCBI chr 9:30,715,602...30,733,746
|
|
G |
Mt1 |
metallothionein 1 |
multiple interactions |
ISO |
[ferric nitrilotriacetate co-treated with Hydrogen Peroxide] inhibits the reaction [MT1 protein binds to Cadmium]; [ferric nitrilotriacetate co-treated with Hydrogen Peroxide] inhibits the reaction [MT1 protein binds to Zinc]; ferric nitrilotriacetate results in increased oxidation of [MT1 protein binds to Zinc] |
CTD |
PMID:22001350 |
|
NCBI chr19:10,831,959...10,832,975
|
|
G |
Mt2A |
metallothionein 2A |
multiple interactions |
ISO |
[ferric nitrilotriacetate co-treated with Hydrogen Peroxide] inhibits the reaction [MT2 protein binds to Cadmium] |
CTD |
PMID:22001350 |
|
NCBI chr19:10,837,934...10,838,708
|
|
G |
Mt3 |
metallothionein 3 |
decreases response to substance |
ISO |
MT3 protein results in decreased susceptibility to ferric nitrilotriacetate |
CTD |
PMID:12383939 |
|
NCBI chr19:10,848,754...10,850,158
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of MYC mRNA; ferric nitrilotriacetate results in increased expression of MYC protein |
CTD |
PMID:18055543 |
|
NCBI chr 7:95,483,105...95,488,031
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
affects localization |
ISO |
ferric nitrilotriacetate affects the localization of NFE2L2 protein |
CTD |
PMID:18617210 |
|
NCBI chr 3:81,001,529...81,031,165
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
EXP |
[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of NFKB1 mRNA; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of NFKB1 mRNA] |
CTD |
PMID:21907755 |
|
NCBI chr 2:226,689,745...226,805,897
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions increases expression |
ISO EXP |
ferric nitrilotriacetate inhibits the reaction [Doxorubicin results in increased expression of NOS2 mRNA]; ferric nitrilotriacetate inhibits the reaction [Doxorubicin results in increased expression of NOS2 protein]; ferric nitrilotriacetate inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] ferric nitrilotriacetate results in increased expression of NOS2 protein [Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of NOS2 protein; chrysin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of NOS2 protein]; chrysin inhibits the reaction [ferric nitrilotriacetate results in increased expression of NOS2 protein]; ferric nitrilotriacetate promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of NOS2 mRNA]; ferric nitrilotriacetate promotes the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA] |
CTD |
PMID:11461780 PMID:11746204 PMID:12490132 PMID:23194824 |
|
NCBI chr10:64,313,335...64,349,221
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression |
ISO |
ferric nitrilotriacetate results in increased expression of NQO1 mRNA; ferric nitrilotriacetate results in increased expression of NQO1 protein |
CTD |
PMID:18617210 |
|
NCBI chr19:52,205,374...52,220,267
|
|
G |
Odc1 |
ornithine decarboxylase 1 |
multiple interactions increases activity |
EXP |
[ferric nitrilotriacetate results in increased abundance of Hydroxyl Radical] which results in increased activity of ODC1 protein; Active Hexose Correlated Compound inhibits the reaction [[ferric nitrilotriacetate results in increased abundance of Hydroxyl Radical] which results in increased activity of ODC1 protein]; Vitamin E inhibits the reaction [ferric nitrilotriacetate results in increased activity of ODC1 protein] |
CTD |
PMID:9667754 PMID:14623030 PMID:15949125 |
|
NCBI chr 6:46,058,439...46,065,148
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of PCK1 mRNA |
CTD |
PMID:16960379 |
|
NCBI chr 3:182,348,572...182,354,521
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of PCNA protein; [ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of PCNA mRNA; [ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of PCNA protein; chrysin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of PCNA protein]; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of PCNA mRNA]; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of PCNA protein] |
CTD |
PMID:21907755 PMID:23194824 |
|
NCBI chr 3:139,951,948...139,955,820
|
|
G |
Phlda3 |
pleckstrin homology-like domain, family A, member 3 |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of PHLDA3 mRNA |
CTD |
PMID:23208426 |
|
NCBI chr13:47,193,250...47,196,335
|
|
G |
Plau |
plasminogen activator, urokinase |
multiple interactions increases expression increases activity |
ISO |
Deferoxamine inhibits the reaction [ferric nitrilotriacetate results in increased activity of PLAU mRNA]; Deferoxamine inhibits the reaction [ferric nitrilotriacetate results in increased expression of PLAU mRNA] |
CTD |
PMID:17571974 |
|
NCBI chr15:3,505,485...3,511,987
|
|
G |
Plk2 |
polo-like kinase 2 |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of PLK2 mRNA |
CTD |
PMID:23208426 |
|
NCBI chr 2:43,702,536...43,708,305
|
|
G |
Pola1 |
DNA polymerase alpha 1, catalytic subunit |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of POLA1 mRNA |
CTD |
PMID:10854235 |
|
NCBI chr X:62,028,475...62,342,455
|
|
G |
Ppia |
peptidylprolyl isomerase A |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of PPIA protein |
CTD |
PMID:16908007 |
|
NCBI chr14:81,279,292...81,282,960
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions increases expression |
EXP |
[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of PTGS2 protein; chrysin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of PTGS2 protein]; chrysin inhibits the reaction [ferric nitrilotriacetate results in increased expression of PTGS2 protein]; Hesperidin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of PTGS2 protein] |
CTD |
PMID:23194824 PMID:30098279 |
|
NCBI chr13:64,714,063...64,722,320
|
|
G |
Ptprb |
protein tyrosine phosphatase, receptor type, B |
decreases expression |
EXP |
ferric nitrilotriacetate results in decreased expression of PTPRB mRNA |
CTD |
PMID:10854235 |
|
NCBI chr 7:51,953,375...52,034,751
|
|
G |
Ptprz1 |
protein tyrosine phosphatase, receptor type Z1 |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of PTPRZ1 mRNA; ferric nitrilotriacetate results in increased expression of PTPRZ1 protein |
CTD |
PMID:18055543 |
|
NCBI chr 4:51,397,316...51,595,220
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased localization of RELA protein; chrysin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased localization of RELA protein] |
CTD |
PMID:23194824 |
|
NCBI chr 1:212,354,336...212,364,815
|
|
G |
Rpl19 |
ribosomal protein L19 |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of RPL19 mRNA |
CTD |
PMID:10854235 |
|
NCBI chr10:83,022,503...83,026,030
|
|
G |
Rprm |
reprimo, TP53 dependent G2 arrest mediator homolog |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of RPRM mRNA |
CTD |
PMID:23208426 |
|
NCBI chr 3:58,948,618...58,950,035
|
|
G |
Rps13 |
ribosomal protein S13 |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of RPS13 mRNA |
CTD |
PMID:10854235 |
|
NCBI chr 1:170,572,925...170,575,355
|
|
G |
Rps15 |
ribosomal protein S15 |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of RPS15 mRNA |
CTD |
PMID:10854235 |
|
NCBI chr 7:9,416,003...9,417,442
|
|
G |
Slc11a2 |
solute carrier family 11 member 2 |
decreases expression |
ISO |
ferric nitrilotriacetate results in decreased expression of SLC11A2 mRNA |
CTD |
PMID:11925462 |
|
NCBI chr 7:131,503,076...131,540,246
|
|
G |
Slc40a1 |
solute carrier family 40 member 1 |
decreases expression |
ISO |
ferric nitrilotriacetate results in decreased expression of SLC40A1 mRNA |
CTD |
PMID:11925462 |
|
NCBI chr 9:55,525,457...55,633,463
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
EXP |
ferric nitrilotriacetate inhibits the reaction [Dimethylnitrosamine results in decreased expression of SOD1 protein] |
CTD |
PMID:15842777 |
|
NCBI chr11:42,942,742...42,948,399
|
|
G |
Ssrp1 |
structure specific recognition protein 1 |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of SSRP1 mRNA |
CTD |
PMID:8844983 |
|
NCBI chr 3:70,124,371...70,134,481
|
|
G |
Tgfa |
transforming growth factor alpha |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of TGFA mRNA; ferric nitrilotriacetate results in increased expression of TGFA protein |
CTD |
PMID:8340253 |
|
NCBI chr 4:120,175,549...120,258,342
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP |
[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TGFB1 mRNA; CYGB protein inhibits the reaction [[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TGFB1 mRNA] |
CTD |
PMID:16581302 |
|
NCBI chr 1:90,324,312...90,340,627
|
|
G |
Tgfb2 |
transforming growth factor, beta 2 |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of TGFB2 mRNA |
CTD |
PMID:23208426 |
|
NCBI chr13:98,160,075...98,261,771
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
multiple interactions |
EXP |
[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TIMP1 mRNA; CYGB protein inhibits the reaction [[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TIMP1 mRNA] |
CTD |
PMID:16581302 |
|
NCBI chr X:3,766,509...3,772,578
|
|
G |
Tnf |
tumor necrosis factor |
increases expression multiple interactions |
ISO EXP |
ferric nitrilotriacetate results in increased expression of TNF protein [Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of TNF protein; chrysin inhibits the reaction [[Diethylnitrosamine co-treated with ferric nitrilotriacetate] results in increased expression of TNF protein] |
CTD |
PMID:15781289 PMID:23194824 |
|
NCBI chr20:3,626,685...3,629,303
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
EXP |
[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of TP53 mRNA; [ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of TP53 protein; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of TP53 mRNA]; geraniol inhibits the reaction [[ferric nitrilotriacetate co-treated with Diethylnitrosamine] results in increased expression of TP53 protein] |
CTD |
PMID:21907755 |
|
NCBI chr10:54,798,871...54,810,300
|
|
G |
Txn1 |
thioredoxin 1 |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of TXN protein |
CTD |
PMID:15834431 |
|
NCBI chr 5:77,507,455...77,519,685
|
|
G |
Txnip |
thioredoxin interacting protein |
decreases expression increases methylation |
EXP |
ferric nitrilotriacetate results in decreased expression of TXNIP protein ferric nitrilotriacetate results in increased methylation of TXNIP promoter |
CTD |
PMID:15834431 |
|
NCBI chr 2:186,781,933...186,785,736
|
|
G |
Ubd |
ubiquitin D |
increases expression |
EXP |
ferric nitrilotriacetate results in increased expression of UBD mRNA |
CTD |
PMID:23208426 |
|
NCBI chr20:1,385,487...1,387,438
|
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
decreases secretion |
EXP |
Lumefantrine results in decreased secretion of FSHB protein |
CTD |
PMID:26811345 |
|
NCBI chr 3:114,003,262...114,007,072
|
|
G |
Prl |
prolactin |
increases secretion |
EXP |
Lumefantrine results in increased secretion of PRL protein |
CTD |
PMID:26811345 |
|
NCBI chr17:38,287,355...38,298,234
|
|
|
G |
A2m |
alpha-2-macroglobulin |
multiple interactions |
EXP |
N(6),N(6)-dimethyladenine inhibits the reaction [Cadmium Chloride results in increased expression of A2M protein] |
CTD |
PMID:15618353 |
|
NCBI chr 4:154,897,770...154,947,787
|
|
G |
Cdh1 |
cadherin 1 |
multiple interactions |
EXP |
N(6),N(6)-dimethyladenine promotes the reaction [Cadmium Chloride results in decreased expression of CDH1 protein] |
CTD |
PMID:15618353 |
|
NCBI chr19:51,402,178...51,471,572
|
|
G |
Cdh2 |
cadherin 2 |
multiple interactions |
EXP |
N(6),N(6)-dimethyladenine promotes the reaction [Cadmium Chloride results in decreased expression of CDH2 protein] |
CTD |
PMID:15618353 |
|
NCBI chr18:8,051,097...8,265,288
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions |
EXP |
N(6),N(6)-dimethyladenine promotes the reaction [Cadmium Chloride results in decreased expression of CTNNB1 protein] |
CTD |
PMID:15618353 |
|
NCBI chr 8:129,517,576...129,544,661
|
|
G |
Lig1 |
DNA ligase 1 |
multiple interactions |
ISO |
N(6),N(6)-dimethyladenine inhibits the reaction [2-chloroethyl ethyl sulfide results in increased phosphorylation of LIG1 protein] |
CTD |
PMID:16700562 |
|
NCBI chr 1:83,243,043...83,281,707
|
|
G |
|